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“The beginning of wisdom is found in doubting; 
by doubting we come to the question, 
and by seeking we may come upon the truth."
- Pierre Abelard
Abstract
The work presented here focuses on a Chinese hamster ovary cell line producing 
monoclonal IgG. A key challenge in the production of mAbs is to produce a 
consistent glycoform profile between batches, since glycosylation can impact 
efficacy. This work examines the effect of time of harvest and means of cell 
removal on the molecular structure of recombinant IgG. The glycosylation status 
of IgG was compared at different stages of fermentation through analysis of intact 
mAb using liquid-chromatography-electrospray-time-of-flight-mass-spectrometry. 
Heterogeneity in glycosylation patterns, as well as C-terminal lysine and N- 
terminal glutamine residues, could be seen in all samples and an increase in the 
proportion of shorter glycans was observed over time of culture, indicating time 
of harvest could impact upon the efficacy of the product. A shear device 
mimicking the feed zone of a large-scale disc stack centrifuge was used to allow 
better prediction of the effects of early stage cell recovery on the structural 
authenticity of the protein. The composition of the intracellular material, in terms 
of H2L2 tetramers, HL dimers and H and L single chains, is clearly different to the 
extracellular intact mAb, however, their relatively low concentration gives little 
change to the overall profile when released into the product stream. Shear rate and 
time seem to have little effect on the molecular structure of the mAb. The effect of 
holding time and temperature before cell removal was also examined. While 
neither seems to have an effect on the glycosylation pattern of the mAb, there was 
an increase in “half-antibodies” with holding time, from 0 h to 24 h, when holding 
at either +4°C or +37°C. This work highlights the importance of looking at the 
interaction between stages and the bioprocessing units as a whole rather than 
single steps.
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1 Introduction
1.1 Cell culture
The following is a brief overview of mammalian cell culture; culture methods and 
types of reactors, to help set the project in context. More detailed reviews are 
available elsewhere Birch and Racher, 2006; Wurm, 2004. Issues that are of 
concern in the work presented here are process performance related; cell 
concentration, cell viability and lysis, antibody formation and titre, culture and 
processing environment etc.
1.1.1 Mammalian cell lines
O f all approved recombinant proteins on the market, about 60-70% are produced 
in mammalian cell lines (Wurm, 2004). This is due to the ability of the cells to 
produce correctly folded and assembled proteins with the right post-translational 
modifications, glycosylation being one of the most important ones. Most 
commonly used are Chinese hamster ovary (CHO) cell lines (Schlatter et al, 2005; 
Sethuraman and Stadheim, 2006) and mouse myeloma (NS0) (Beck et al, 2005). 
To a smaller extent baby hamster kidney (BHK) cell lines are also used. CHO cell 
lines are currently the most widely used due to the knowledge and experience that 
exist and is constantly growing in the industry.
1.1.2 Selection method
In order to cultivate the cells containing the product of interest a selection step is 
needed. In the case of monoclonal antibody (mAb) production the selection step is 
required to select the successfully fused hybridomas that produce the desired 
antibodies. This is done prior to fusion by introducing an additional gene into the 
B-cell that will then translate into a protein that the cells can be selected for. In 
mammalian cell culture the most commonly used genes are those for glutamine 
synthetase (GS) and dihydrofolate reductase (DHFR). Selection is then carried out 
in media lacking the relevant metabolite (hypoxantine and thymidine for DHFR 
and glutamine for GS), preventing cells that have not been transformed from
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growing and providing a way of removing the myeloma cells that lack the gene 
coding for the selected protein. The cells are then further cultivated and analysed 
in order to obtain the clone with the most efficient antibody production for large 
scale cultivation.
1.1.3 Media
The medium is usually made up of the following components; carbohydrates, 
amino acids, salts, bicarbonate, vitamins, hormones and supplements. Glucose is 
the most commonly used carbon and energy source and it also serves as a 
precursor for biosynthesis, such as ribose, which is needed for nucleic acid 
synthesis. Amino acids are added as precursors for protein synthesis. Salts are 
added to keep the solution isotonic in order to prevent imbalances with the 
intracellular content. Bicarbonate is added to serve as a buffer system together 
with gaseous carbon dioxide to keep the pH stable around 7 as in the natural 
environment of the cells inside the body. Vitamins and hormones work as 
metabolic cofactors, while supplements are added to aid cell growth. The 
traditional supplement is serum, e.g. foetal calf or bovine. However this contains 
undefined materials that can cause inconsistency between batches, the proteins it 
contains can cause problems during purification and it is also prone to 
contamination with viruses and prions. These are the main reasons the industry 
has been working towards serum free media, which is not as complex, easier to 
define and to ensure purity after downstream processes for validation purposes. 
Instead of serum, bovine serum albumin (BSA) or similar can be added to the 
media. However, this still introduces problems such as contaminating host cell 
proteins. The result can be a product that contains unacceptable levels of bovine 
IgG (Rasmussen et al, 2005). The levels of bovine IgG could be reduced by using 
protein A affinity chromatography and not protein G when purifying the protein, 
if the product has affinity for both staphylococcal protein A (SpA) and 
streptococcal protein G (SpG) (see section 1.2). Instead of serum or BSA, other 
nutrients can be added, creating a protein free (animal component free) or 
chemically defined media, which is the subject for constant ongoing research in 
order to develop a highly productive cell culture. Standard media is available from
15
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suppliers, but most companies invest time and money in optimising the contents 
to suit their own processes and to obtain maximal productivity.
1.1.4 Culture conditions
Mammalian cells are most stable around neutral pH and at 37°C for obvious 
reasons. Cells can handle a lower temperature than the optimum, but the growth 
rate will decrease. If the temperature increases slightly however, the cells are not 
as tolerant and this would lead to cell death. Temperature is usually controlled 
through coiled pipes in large scale reactors or through a jacket for lab-scale 
fermenters. A bicarbonate-CC>2 buffering system can keep pH in the range of 6.9- 
7.4, but it is also common to add a buffer to aid the buffering capacity. pH is 
controlled by direct addition of acid or alkali, normally only alkali due to the 
formation of lactic acid, which brings the pH of the broth down.
1.1.5 Culture method
There are two main methods of cultivating mammalian cells; adherent and 
suspension culture, the latter one being the most widely used.
1.1.5.1 Adherent
In adherent culture, media is added to roller bottles to a level of 10-30% of the 
total volume. Cells are then seeded into the bottles that are slowly rotated, 
allowing cells to adhere and to be wetted while the large head space supplies them 
with oxygen. The roller bottle system is easily scaled up by increasing the number 
of bottles; however, the titres obtained are lower than that for suspension cultures 
due to the lower cell/reactor volume ratio (Wurm, 2004), causing limitations in 
the use of the system. Adherent culture can also be carried out in bioreactors with 
the use of microcarriers, cultivated in stirred tank reactors. This allows the use of 
cells not capable of growth in suspension to make use of the scale-up efficiency of 
the stirred tanks.
16
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7.7.5.2 Suspension
Suspension culture is the most commonly used method due to the wide knowledge 
available about the stirred tank system. It is also easy to scale up in order for large 
scale production to be carried out once the culture conditions have been 
determined.
7.7.5.3 Batch/Fed-batch
The most basic mode of operation for cell culture is the batch mode. Here the 
medium and the inoculum are placed in the reactor before the start of the culture. 
The culture is then run for as many days as required and the contents then 
harvested. The disadvantage of batch mode is that the cells are using the same 
media the entire time and there is therefore a risk of exhausting vital nutrients or 
energy sources. It also results in the build up of metabolites that can be growth 
inhibiting. A modification to this method is the fed-batch process. This involves 
the addition of fresh media at one or more time points between beginning and end 
of culture. The addition supplies the cells with fresh nutrients and energy sources 
aiding cell growth and protein production. On the downside it could also be an 
extra source for contamination, so care must be taken in order to prevent this. Fed- 
batch is today the most commonly used mode of operation in large scale mAb 
production and allows for high cell densities to be achieved.
7.7.5.4 Perfusion
The perfusion culture was introduced in order to further aid cell growth and 
culture performance. This involves the constant addition of fresh media while 
harvesting is carried out so that the volume stays constant. The additions of fresh 
media keep the nutrient levels up and metabolite levels down. At the same time it 
protects the product from possible degradation that can occur if kept for too long 
in the vessel (e.g. from the release of proteolytic enzymes). The feeding aids in 
keeping a high cell viability and in reaching higher cell densities. Over the last 
few years, high cell densities have been the focus of a lot of research in order to 
improve process economics, so perfusion culture is becoming a more popular 
mode of operation. At the moment there are a few different retention devices used 
at large-scale in industry, including the spin-filter system, the inclined settling
17
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device and the ultra-sound retention device (Merten, 2006).
1.1.6 Type of reactor
There are many different types of reactors on the market at the moment, but there 
are some that are more commonly used than others, like the stirred tank reactor, 
airlift fermenter and the hollow-fibre reactor. There have also been disposable 
systems emerging over the past decade, one of the most popular being the Wave 
bioreactor (Wave Biotech, GE Healthcare, Somerset, NJ).
1.1.6.1 Stirred tank reactor
The stirred tank reactor is the basic design that has been used for years in bacterial 
fermentations and there is therefore an extensive know-how about this system and 
scale-up is well understood. Since mammalian cells are different to bacterial ones, 
stirred tanks for animal cells have a slightly different design and operation, but the 
basics are still the same. Stirred tank reactors at lab-scale are usually made of 
glass, while large scale vessels are made of stainless steel. Agitation is provided 
by impellers that are usually top-driven. Since mammalian cells are more fragile 
than bacterial, the impellers are normally operated at lower stirring speeds. If 
microcarriers are used, the stirrer speeds used are even lower. The bottom of the 
vessel is round in order to aid mixing. Suitable impellers are the marine and 
pitched blade types that provide both vertical and horizontal mixing. At lab-scale 
enough oxygen is supplied through surface aeration. At larger scale sparging is 
required for oxygen supply. The disadvantage of this is the damage it can cause to 
the cells through bubble breakage at the surface and the excessive foaming which 
may occur.
1.1.6.2 Airlift fermenter
An airlift fermenter has a higher aspect ratio (heightiwidth) than a regular stirred 
tank reactor. It has a draught tube inside the vessel, at the bottom of which air is 
sparged providing fluid circulation in an upward movement inside the tube 
(Figure 1.1). This provides aeration and agitation at the same time, without any 
mechanical input, creating a system with lower energy consumption, hence lower
18
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operating costs. It also provides milder conditions for the cells and so reduces cell 
damage.
7.1.6.3 Hollow-fib re reactor
The hollow-fibre reactor (Figure 1.2), based on the kidney dialysis system, 
consists of synthetic, semi permeable hollow fibres. The media is pumped into the 
intracapillary circuit (IC) inside the fibres where nutrients and gases are 
exchanged, through the capillary wall, with the extracapillary circuit (EC), which 
contains the growing cells. The molecular weight cut-off of the fibre is such that 
the cells and large molecular weight products are kept in the EC, while the 
pressure inside the fibres pushes the nutrients from the media through the wall. 
The system allows for product and dead cells to be removed from the EC 
throughout the culture and can therefore be run for months at a time. It is however 
not suitable for scale-up due to nutrient gradients and uneven cell growth.
7.7.6.4 Wave bioreactor
As a solution to the costly and time consuming cleaning, sterilisation and 
validation procedures connected with reusable equipment, the Wave bioreactor 
was created. This is a sterile disposable bag, partially filled with media, placed on 
a rocking table that creates a wave-like motion and provides agitation and aids gas 
transfer. The head space in the bag is filled with air to provide oxygen and with 
CO2 to lower the pH accordingly. The system is commonly used at lab-scale, 
providing a mean of increasing the speed of production towards early stages of 
development for evaluation, but can be used for volumes up to 1000 L. The 
system has been shown to exhibit good batch-to-batch reproducibility as well as 
comparable biomass and recombinant protein titres to the stirred tank system, for 
an NSO, a CHO and an insect cell line (Fries et al, 2005). It can be used for 
suspension culture and with the help of microcarriers and is also a good 
alternative for virus production due to the ease of containment (Singh, 1999).
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Gas outlet
Air inlet
Figure 1.1 Schematic o f an airlift fermenter
The vessel contains a draught tube through which air is sparged in an upward 
motion. This provides oxygen to the broth aiding cell growth. It also provides 
agitation that is less harsh as compared to mechanical impellers. The liquid flow  
is circulated back down on the outside o f the draught tube, mixing with the air 
inlet at the bottom and pushed upwards again. Any waste gases are removed 
through the top o f  the vessel.
20
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Product
Waste +
Extracapillary 
circuit
* H- Media
Intracapillary circuit
Figure 1.2 Schematic o f the hollow fibre system
Media is pumped through the inside o f  the fibres -  the intracapillary circuit (1C) -  
providing the cells with fresh nutrients. The media is pushed through the fibres 
creating a higher pressure, which will aid the exchange o f nutrients and gases 
with the extracapillary circuit (EC). The cells are kept in the EC together with the 
large molecular weight products by the cut-off o f the fibre and can make use o f  
fresh nutrients and energy sources throughout the culture thanks to this recycling 
system. Waste containing low molecular weight compounds can be removed and 
disposed o f from the 1C, while product is extracted from the EC allowing fo r  
higher cell densities.
21
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1.2 Downstream processing
The following is a brief introduction to the downstream processing related to mAb 
production, which is followed by more detailed reviews on issues that are of 
concern in the work presented here, such as harvest, processing conditions and 
antibody structure to mention a few. Further details on antibody purification can 
be found elsewhere (Gottschalk, 2005; Gottschalk, 2008; Jagschies et al, 2006; 
Shukla et al, 2007).
The standard purification sequence for monoclonal and polyclonal antibodies is 
centrifugation, microfiltration, protein A/G chromatography and finally ion 
exchange chromatography. This is in order to achieve the high degree of purity 
required for use as therapeutic agents.
Centrifugation clarifies the broth so that only the antibody-containing supernatant 
can be further processed. This technique involves high shear forces that could 
have a deteriorating effect on the product and could also lead to aggregation. 
Therefore it is of particular importance to confirm the structural integrity and 
general quality of the product after this step.
The absence of debris in the broth is of great importance due to the high cost of 
the protein A matrix (see below). It is therefore crucial to remove solid material 
that can cause column fouling. Microfiltration is often used after centrifugation to 
further minimise the level of particulates and achieve the required purity needed 
for the chromatography steps.
Protein A/G matrices are rather expensive and it is therefore of importance to keep 
the number of runs per column high by introducing a clear feed stream. The 
matrices are developed from staphylococcal protein A (SpA) and streptococcal 
protein G (SpG) respectively. Both proteins bind to immunoglobulin providing a 
highly specific affinity chromatography technique. Protein A is obtained from 
Staphylococcus aureus, while protein G is produced by species of Streptococcus 
(Bjorck and Kronvall, 1984). It has been commonly accepted that SpA and SpG
22
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bind to the Fc part of the Ig molecule. However, more recent publications show 
several binding sites on the antibody. For example one study used papain digested 
IgG (resulting in Fab and two Fc, distinguished as a high and a low molecular 
weight fragment) fragments and it was observed that SpA bound only to the high 
molecular weight Fc fragment, while SpG bound to Fab and also the low 
molecular weight Fc fragment (Aybay, 2003). Protein A/G affinity 
chromatography is a highly specific purification method where excellent yields 
and purities can be obtained. One study reported yields of up to 100% and purities 
over 99% (Fahmer et al, 1999). A problem with protein A chromatography is the 
leakage of ligand into the eluted material. This has to be removed together with 
other contaminants such as host cell proteins by cation and/or anion 
chromatography in order to obtain a product of the required purity.
1,3 Scales and dosages
The doses required for in vivo usages of mAbs are relatively large. Common 
dosages for intravenous infusions are similar to that of Herceptin (Genentech, San 
Francisco, CA, USA) at 4 mg/kg bodyweight as a first injection, followed by 2 
mg/kg weekly. For intramuscular injections the dosages are even higher, as for 
Synagis (Medlmmune, Gaithersburg, MD, USA), which requires 15 mg/kg. This 
puts pressure on companies to meet the high demand and there is therefore a 
constant search for ways to increase the productivity. Over the past decades there 
has been a great increase in product titres, now a common titre is 2 g/L for mAbs 
in cell culture (Wurm, 2004). This has been achieved by extensive research in 
areas of genetic engineering and optimisation of media, cell culture format and 
important cultivation parameters such as temperature, pH, and harvest time. 
Lately there have even been reports of mAb titres of 5 g/L and above (Jagschies et 
al, 2006). The scale of operation has also increased rapidly over the past decades. 
Lonza (Portsmouth, NH, USA) is now operating a 20,000 L process for the 
production of recombinant mAb and perfusion processes are run elsewhere 
(Centocor Inc., Horsham, PA, USA) up to a scale of 500 L for mAb production 
(Merten, 2006).
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1.4 Challenges and trends in cell culture
Over the past decades, research has improved and made economically feasible the 
production of therapeutic proteins using mammalian cell lines. This research has 
focused on the understanding of the mammalian cell system and has provided 
knowledge about cell physiology and growth characteristics. Improvements have 
been made through host cell and metabolic engineering, medium development and 
screening methods. This has resulted in better productivity including higher cell 
densities and product titres. An example comparing a stirred-tank process in 1986 
and one in 2004 claims an increase in cell density from 2 x 106 cells/mL to 10 x 
106 cells/mL, an increase in specific productivity from 10 pg/cell/day (PCD) to 90 
PCD, and a close to 100-fold increase in mAb titre from 50 mg/L to 4.7 g/L 
(Wurm, 2004). The cell densities now achieved in mammalian cell culture are 
nowhere near what can be achieved in microbial cultures, so this is still a very 
important area for further research to improve productivity.
So far most research has focused on cell engineering and optimisation as well as 
the cell culture process in order to achieve higher cell densities and product titres. 
What will naturally then be needed is more research into downstream processes to 
cope with these high cell densities. There are processes in place to deal with high 
microbial cell densities, but due to the more fragile nature of the mammalian cells, 
these may not be suitable for this purpose. Even more importantly, the product 
quality must be carefully monitored to keep a consistency and to assure the 
product safety. This calls for standard procedures and protocols to be established 
for the analysis of the protein products.
Another issue that has been in focus over the last few years is the choice between 
reusable and disposable equipment. Disposable equipment may seem like a more 
expensive option, but reusable equipment is subject to extensive, time consuming 
and costly cleaning, sterilisation and validation procedures in order to prevent any 
cross-contamination between batches. Disposable equipment is therefore a very 
much up-and-coming alternative in mammalian cell culture.
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1,5 Centrifugation
The first harvest step following fermentation in the production process of 
biopharmaceuticals is perhaps the most important one, since any losses of, or 
modifications to the product here will have a great impact on all subsequent 
purification steps. Centrifugation is the most commonly used harvest method for 
different types of cell culture, including mammalian, due to the relatively short 
processing times and the effectiveness in clarification. The main purpose of the 
harvest step is to separate the cells from the liquid broth, whether the product is in 
the supernatant or inside the cells or if the cells are the actual product. Any lack of 
performance will have a knock-on effect on any further purification steps, for 
example the commonly used subsequent filtration step, that will be prone to 
clogging and larger filtration areas will be needed. If the filtration step does not 
perform to the required standard, this will then cause expensive chromatography 
matrices to foul, causing increases in processing costs and decreases in product 
yield and purity. Centrifugation is an established separation method that is based 
on the principles of sedimentation, utilizing density differences between the cells 
and the liquid broth. The sedimentation properties for gravity settling are 
represented by Stoke’s law, which if assuming the cells are spherical takes the 
form:
Pp P  f  T\ 2 / 1  1 \
u ' = - w ~ D ' g  ( l l )
where ug is the terminal sedimentation velocity, pp is the density of the particle, pf 
is the density of the liquid, p is the viscosity of the liquid, Dp is the particle 
diameter and g  is the gravitational acceleration. The terminal velocity can 
similarly be represented for a particle in a centrifuge:
P p  P f  n  2u —  —D o o r  ( 1.2)
18// 77 V }
where uc is the particle velocity in the centrifuge, co is the angular velocity of the 
bowl (rad s '1) and r is the radius of the centrifuge.
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Equations 1.1 and 1.2 can be related using the centrifuge effect (Z):
g
The centrifugal field experienced in a centrifuge is commonly expressed as 
multiples of the gravitational acceleration and is then called the relative 
centrifugal force.
From equation 1.2 it becomes obvious that the rate of sedimentation in a certain 
centrifuge at a certain speed depends on a few important properties; the size and 
density of the particles and the density and viscosity of the liquid broth. One 
important aspect to note here is that the smaller the particle, the lower the rate of 
sedimentation, i.e. the less efficient will the centrifugation process be and so for 
batch processes higher angular velocities are needed exposing the product stream 
to higher shear rates (see section 1.5.2), or longer processing times are required. 
For a continuous operation the residence time within the centrifuge is increased by 
decreasing the flow rate.
There are different types of large-scale centrifuges that are used in industry for 
clarification of cell culture broths. Some are capable of continuous flow, while 
others work as a batch operation requiring manual solids discharge.
The tubular bowl centrifuge is a simple semi-continuous model that has been used 
in industry for many years. It is operated vertically and consists of a long cylinder 
that rotates inside a stationary casing so that when the broth is fed up through the 
cylinder the solids are forced outwards and stick to the walls, while the liquid 
flows up towards the top of the tube. The way the system is set up prevents 
continuous operation due to solids build-up and requires stopping, dismantling 
and manual removal of the cell debris.
The chamber bowl is a batch operated centrifuge that consists of one big bowl 
containing several tubular bowls with increasing diameter, where the broth is
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introduced from the bottom centre and is fed through the cylinders. The solids 
stick to the walls of the chambers while the liquid proceeds through the whole 
system and can be collected at the outlet. This set-up requires a batch-operated 
process where the centrifuge has to be stopped and the solids manually removed.
An example of a continuously operating centrifuge is the disc stack. It consists of 
a rotating bowl filled with stacked plates at a downward angle (Figure 1.3), which 
provides an increased settling area, allowing for a faster process. When the bowl 
rotates the solids are forced outwards against the wall of the bowl, as well as the 
discs, while the clarified liquid continues to flow up along the axis and towards 
the outlet at the top of the bowl. The solid paste can be removed continuously, 
intermittently or manually, depending on the complexity of the system.
1.5.1 Sigma theory
Sigma theory is a concept used in centrifuge scale-up. It describes the 
characteristics of the centrifuge related to that of an equivalent sedimentation 
process without any force applied, i.e. from gravity alone. The characteristic this 
is described by is the equivalent settling area, sigma (£, m2) and for a continuous 
centrifuge the sigma factor can be related to the feed rate through the following 
equation:
where Q is the volumetric feed rate. The sigma concept allows comparison of 
different types of centrifuges, as well as centrifuges of different scale, through the 
following equation.
- 0 _  = _ £ L  (, 5)
I ,£ , E2£ 2
where Q\ and Q2 are the volumetric flow rates of centrifuge 1 and 2 respectively,
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Ei and E2 are the sigma factors of centrifuge 1 and 2 respectively and E\ and E2 
are the correction factors of centrifuge 1 and 2 respectively.
When using sigma theory to compare centrifuges of different types or scale, one 
of them is set as base case and its correction factor is set to 1. The correction 
factor for the centrifuge it is being compared to can then be looked up in 
literature.
The type of lab-scale centrifuge used in this work was a bottle swing out rotor 
type. The equivalent settling area for this type is defined as (Maybury et al, 2000):
where x and y  are the fractions of total time required for acceleration and 
deceleration respectively, Viab is the volume of the sample, rj and are the radii 
of the surface of the centrifuge liquor and the base of the centrifuge tube 
respectively. For a disc stack centrifuge, the equivalent settling area is expressed
where N  is the number of discs, rQ is the outer radius of the disc, r, is the inner 
radius of the disc and 0 is the half-cone angle of the disc. When comparing a batch 
type small scale centrifuge, such as the bottle swing out rotor, to a large scale 
continuous type, such as the disc stack, equation 1.5 becomes:
eo2 (3 - 2 x -  2y)Vlab
( 1.6 )
ln(— —)6g
r,+r.
by:
_ Inco1 (N  -1 ) 
3 g  tan 0
(1.7)
( 1.8)
where tiab is the residence time of the small scale batch centrifuge.
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Figure 1.3 Schematic o f a disc stack centrifuge
The fermentation broth is fe d  in through the top and travels down the middle and 
when the centrifuge spins around its own axis the broth is forced out towards the 
sides o f  the chamber and up through the spacing o f the disc stacks. The solids 
settle on the disc stacks and the walls o f the chamber and can be removed 
intermittently or manually.
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1.5.2 Shear
During production and purification of biologic materials, such as therapeutic 
proteins, the product stream is exposed to possibly damaging hydrodynamic as 
well as mechanical forces. Although there are many causes of damage to cells, the 
main physical causes relate to shear and elongational flow stresses (Yim and 
Shamlou, 2000). Some of the main concerns are the shear forces experienced 
during centrifugation. Shear is not only experienced during centrifugation, but 
also in other unit operations, such as bioreactors, but to a much lesser extent. 
Shear can also be experienced during transport of the material through pumping. 
The damaging forces are generally expressed as a function of the energy 
dissipation rate (Wkg'1) and the magnitude can vary widely between different
5 7 1types of centrifuges, but can be in the range of 10 -10 Wkg' , which is nearly as 
high as the energy dissipation rate in a homogeniser (107-109 W kg'1 (Yim and 
Shamlou, 2000).
In order to be able to design suitable processes and to produce consistent and safe 
therapeutics, the effects of shear forces have to be investigated and understood. 
Several studies have been carried out looking at the effects of shear on various 
biomaterials and shear in combination with other possibly damaging factors, such 
as temperature and air-liquid interfaces. A lot of these studies were carried out 
using various enzymes but not all of them report major damage due to shear. One 
study looked at the effects of shear, temperature and adverse pH conditions on 
yeast alcohol dehydrogenase (ADH) (Thomas et al, 1979). They found that 
shearing made the solutions turbid without causing large activity losses (only 
-2%). Experiments at a higher temperature caused precipitation, but this was 
assigned to temperature rather than shear, while adverse pH conditions did not 
seem to contribute to shear damage. Supporting these findings are studies where 
shearing by a concentric-cylinder device did not cause losses in activity of ADH 
(Virkar et al, 1981). These studies also looked at the effect of shear experienced in 
pumps, with negligible damage to ADH in a single pass, but with excessive 
numbers of passes they saw a decrease in enzyme activity. Further studies 
(Thomas and Dunnill, 1979) on bovine liver catalase and jack bean urease saw no 
losses in activity due to shear. When reproducing previous experiments by other
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groups, they noted much lower losses than reported previously. This led to 
repeating the experiments with enzymes from different suppliers where no losses 
of activity was noted for the enzyme from one supplier, while a 27% decrease was 
noted from the other supplier. This is strong evidence of the complexity of 
biologic material and hydrodynamic forces and highlights the importance of 
looking at different materials in order to draw conclusions regarding shear 
damage. One study used a stirred vessel to investigate the effect of shear in the 
presence of air-liquid interfaces on recombinant single chain antibody fragments 
(scFv) produced in E.coli (Harrison et al, 1998). Activity losses of up to 80% 
were recorded for stirred scFv in buffer, while stirred scFv in fermentation broth 
showed no losses. The antifoam was thought to have provided the protected 
environment in the latter case. It is obvious that even though shear might not be a 
major cause of concern to some biologic materials, it will have a great impact on 
others. It is also not only the active product that can be affected by shear. 
Hutchinson et al. (2006) showed that shearing of mammalian cell culture caused a 
decrease in particle sizes, which in turn heavily affected the clarification 
performance and would then affect all following purification stages and the 
overall process economics.
1.5.3 Ultra scale-down
In the pharmaceutical industry there are many factors affecting the process from 
research to commercial production of the completed product. In contrast to other 
areas, cost is not necessarily always the major determinant. Instead, other factors 
play an important role. The degree of purity, for example, that is required for 
injection is extremely high and has to be obtained at all cost, otherwise the 
product will never reach the market. One of the most important factors in this fast- 
moving industry is time. It is a highly competitive market, with many companies 
working on similar products. It is therefore of vital importance for a company to 
secure patents and have its product reach market first. This calls for quick 
decisions and a need to often start the next stage in the development process even 
before the previous one is complete. During the development of new products 
there are usually only very limited amounts of material available and this material 
is often also very expensive. This means that process development needs to be
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carried out at a small scale before long and expensive trials at large scale can be 
carried out. The results obtained from the small-scale experiments have to be 
possible to correlate to the large scale so that predictions can be made. Many rules 
for scale-up have been determined over the years and for some unit operations 
good correlations have been achieved. There are, however, further challenges 
even where these procedures have been established; not only microbial and yeast 
cultures are being used, but also shear-sensitive mammalian cultures for example, 
that have different properties and require other variables to be taken into 
consideration.
On the other hand, there is also a need for large-scale processes already in use to 
be mimicked at small scale for further investigations, analysis, and possible 
process changes. This could significantly decrease the time and cost of future 
developments.
The problems experienced in scale-down/scale-up of centrifuges mainly relate to 
differences in the fluid flow. The lab-scale equipment that is available is 
geometrically very different to the industrial-scale centrifuges and flow of 
material will therefore be very different, which in turn causes differences in forces 
acting upon the broth. To be able to predict the performance of the large-scale 
equipment, these forces need to be modelled if a true mimic is to be created.
Several attempts to scale down centrifugation have been carried out. One of these 
managed to scale down an industrial-size disc stack centrifuge 10-fold by 
reduction of the separation area (Mannweiler and Hoare, 1992). The scale-down 
model successfully predicted the recovery of polyvinyl particles. This model 
however still requires fairly large process volumes. A similar approach was taken 
where inserts were used to reduce the separation area by 76% and the bowl 
volume by 70% (Maybury et al, 1998). In a later study (Maybury et al, 2000) a 
bench-top centrifuge was instead used to mimic the performance of a large-scale 
continuous disc stack centrifuge. To carry out the study sigma theory was utilized, 
but the important acceleration/deceleration times for the small-scale centrifuge 
were taken into account and incorporated into the sigma factor. The study found 
that the recovery of shear-insensitive material, such as polyvinyl acetate particles
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and yeast cell debris, was well predicted, while for shear sensitive material, such 
as protein precipitates, the recovery was over-predicted due to solids break-up.
1.5.4 Shear device
Work carried out at University College London has resulted in a miniature shear 
device being constructed (Levy et al, 1999), mimicking the high shear forces 
experienced in large scale centrifuges. This system is using an ultra scale-down 
(USD) approach to perform experiments on the millilitre scale. The device was 
developed by application of computational fluid dynamics (CFD) in order to 
predict the energy dissipation rates in the feed zone of an industrial disc stack 
centrifuge. A rotating disc device was then constructed mimicking the same rates. 
This device can be used as a time saving and cost efficient research tool for 
investigations of effects of centrifugation in bioprocessing and the potential 
damage to proteins caused by the shear experienced (Boulding et al, 2002; 
Boychyn et al, 2001; Boychyn et al, 2004; Levy et al, 1999; Neal et al, 2003). It 
can be valuable in the early development stages of biological products, such as 
therapeutic proteins, when often only a small amount of material is available. 
Another useful aspect lies in predicting the large-scale process and for developing 
process solutions in a very rapid manner allowing for a quicker route to the 
market. It can also be of use when changes are to be made for an already existing 
process in order to evaluate any effects these changes could have on the product. 
The device used in these studies was a modified version of that described by Levy 
et al. (1999). It was made of stainless steel with a 1 mm thick rotating disc, 40 mm 
diameter, inside a chamber of 50 mm diameter and 12 mm height (see Figure 1.4). 
The speed of the disc is correlated to the shear experienced in the feed zone of a 
centrifuge by CFD, which has been done previously (Boychyn et al, 2001; 
Boychyn et al, 2004). The work carried out here was building upon results from 
studies carried out by Hutchinson et al. (2006), successfully correlating the shear 
rates of the disc device to that of various large-scale centrifuges, and similar 
energy dissipation rates were therefore used.
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Figure 1.4 Schematic o f  the shear device
The shear device used in the studies was a cylinder made o f stainless steel with a 
rotating disc inside it, mimicking the shear experienced at the inlet o f a large- 
scale centrifuge. The disc was 1 mm thick, 40 mm diameter, while the chamber 
had an inner diameter o f 50 mm and 12 mm height (schematic from McCoy, 
2009).
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1.6 Antibodies
Antibodies are vital parts of the human immune system. They are produced by B 
lymphocytes and are distributed throughout the body in the biologic fluids. During 
the immune defence, antibodies that are secreted from the B cells bind to the 
foreign antigen and puts defence mechanisms into place that leads to elimination 
of the antigen. Antibodies work in the immune defence in several ways that are all 
initiated by the binding of the Fab part (see Figure 1.5) of the antibody to the 
antigen on the infected cell. This then activates response mechanisms in the Fc 
part in order to destroy the antigen. These mechanisms are interactions with 
specific ligands, e.g. the Cl component of the complement cascade and the 
cellular receptors, FcyRs (Abbas et al, 2000). The FcyRs are part of the antibody- 
dependent cell-mediated cytotoxicity (ADCC) mechanism. This is where the Fc 
receptors on natural killer (NK) cells recognise and bind to the Fc part of the 
antibody. This in turn triggers a response from the NK cells that causes apoptosis 
of the infected cell. The Fc receptors that bind to IgG are called FcyRs. The other 
mechanism of action for IgG is complement-dependent cytotoxicity (CDC). This 
is initiated by the binding of antibodies to antigens on the infected cell and the 
binding of the antibody to the C 1 component of the complement cascade, which in 
turn punctures the infected cell membrane and causes the cell to lyse and therefore 
die. ADCC and CDC are the two most common mechanisms by which today’s 
approved mAbs work.
1.6.1 Commercial production of antibodies
During the past decades, there have been immense advancements in the area of 
treating diseases with biological products, such as therapeutic proteins. Over the 
past few years in the late nineties and beginning of the new century, the Food and 
Drug Administration (FDA) has approved new drugs treating some of the most 
common diseases that have been difficult to treat before. A large proportion of the 
therapeutic proteins that have been licensed or are presently in clinical trials are 
mAbs. By the end of 2002, there were twelve antibodies, antibody fragments or 
conjugated antibodies approved by the FDA (Harris et al, 2004). To date, there are 
mAbs that have been approved for all sorts of cancers (non-Hodgkin lymphoma, 
breast cancer, leukaemia and colorectal cancer, to mention a few) and other
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diseases such as multiple sclerosis. Many of these are genetically engineered 
mouse mAbs, which have been made to look like human mAbs, examples 
including trastuzumab (Herceptin® by Genentech, Inc, South San Fransisco, CA) 
for breast cancer, cetuximab (Erbitux™ by ImClone Systems Inc, New York, NY) 
for colorectal cancer, daclizumab (Zenapax® by Hoffman-La Roche Inc, Nutley, 
NJ) to help prevent acute kidney transplant rejection and palivizumab (Synagis® 
by Medlmmune, Inc, Gaithersburg, MD) to protect high-risk infants against 
respiratory syncytial virus disease. Another important advancement in 
biotechnology is the first radiopharmaceutical product that was approved in 2002; 
ibritumomab tiuxetan (Zevalin®) that is used together with rituximab (Rituxan®, 
both by Cell Therapeutics, Inc. Seattle, WA) to treat non-Hodgkin’s lymphoma. 
All of these therapeutic proteins are produced on a large scale for commercial 
exploitation. Many of them have been fast-tracked for approval due to the urgency 
of developing drugs targeting diseases that have so far been untreatable.
1.6.2 Basic structure
There are five different classes of antibodies, which are all soluble proteins of 
globular structure with a common name of immunoglobulins (Igs). All antibodies 
share the same core structure of 4 polypeptide chains, two heavy (H) and two light 
(L), held together covalently by disulphide bonds and by non-covalent 
interactions between the chains. The entire core structure has a molecular weight 
of around 150,000 Da, the light chains of approximately 25,000 Da and the heavy 
of 50,000 Da each. Both heavy and light chains contain a series of repeated 
homologous units, creating intrachain disulphide bonds that cause the protein to 
fold into a number of globular domains. Light chains have 2 domains each while 
heavy chains have 4 or 5.
All antibodies have constant carboxy terminal regions (C), which are identical 
within a class, while the amino terminal regions are variable (V). The variable 
region is the part that binds to the epitopes. The N-terminal amino acids of both 
heavy and light chains contain regions of sequence variability different in 
antibodies produced by one clone of B cells from those produced by another. 
There are three short stretches of greatest variability, the hypervariable regions,
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while the less variable stretches in-between are the framework regions. The 
hypervariable regions are also called complementarity-determining region (CDR) 
1, 2 and 3, since they bind the antigen by complementarity.
The light chains are divided into two major classes, kappa (k ) and lambda (>,); 
however one immunoglobulin molecule only contains one class. The heavy chains 
are divided into five major classes, which provide the differentiation of the 
immunoglobulin classes (isotypes). The differences can be found in the constant 
region of the heavy chains and the different types are called alpha (a), delta (8), 
epsilon (e), gamma (y) and mu (p), corresponding to the isotypes IgA, IgD, IgE, 
IgG and IgM respectively. As with the light chains, one immunoglobulin 
molecule only contains one class of heavy chain. The different classes contain 
different numbers of immunoglobulin domains in the constant region of the heavy 
chain, which are numbered ChI, Ch2 etc. (Figure 1.5) from amino to carboxy 
terminus. Human IgA, IgD and IgG contain three domains each, while IgE and 
IgM contain four. IgA and IgG are further divided into two and four subclasses 
respectively, where minor differences occur, mainly concerning the interchain 
disulphide bonds. The structural variations in the different classes of 
immunoglobulin provide a way of producing different effector mechanisms when 
the antibody binds to an epitope. This is due to the heavy chain constant regions 
binding to, for example, proteins from the complement cascade and the structural 
variations causing the binding of different complement proteins.
Of the major classes of immunoglobulin, IgG is the most abundant in humans. 
IgG has the longest half-life of the immunoglobulins of up to 23 days, depending 
on the subclass, and is therefore the most suitable for passive immunization. The 
subclasses that exist are; IgGl, IgG2, IgG3 and IgG4, with IgGl being the most 
abundant in serum and IgG4 the least. A common feature for all classes of 
immunoglobulins is an area containing a large number of cysteine and proline 
residues providing interchain disulphide bonds and preventing globular folding. 
This area, in certain isotypes located between CH1 and Ch2, is called the hinge 
region due to the flexibility it confers on the molecule. The immunoglobulin 
molecule can be cleaved at the hinge region by the proteolytic enzyme papain. 
The enzyme cleaves N-terminally to the disulphide bridge between the heavy
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chains. This results in three approximately equal sized fragments; two of these 
carry the antigen binding sites, Fab (antigen binding fragment) while the third one 
provides the immunological response after antigen binding. This last fragment can 
be crystallised out of solution and is therefore called Fc (crystallisable fragment) 
(Figure 1.5). Immunoglobulins can also be cleaved by pepsin. This enzyme 
cleaves C-terminally to the disulfide bridge between the heavy chains at the hinge 
region. This results in the separation of the Fc fragment from the two Fab 
fragments, that are this time held together by disulfide bridges and called F(ab’)2 . 
The Fc fragment is further cleaved along both chains into several fragments 
(Abbas et al, 2000; Coico et al, 2003; Tizard, 1995).
1.6.3 Formation in the cell
Antibodies occur in both secreted and membrane bound forms. They are produced 
by B lymphocytes in the bone marrow, where the membrane bound antibodies 
form part of the B cell antigen receptor. The secreted antibodies are found in 
blood plasma and other extracellular fluids such as mucosal secretions and also in 
the interstitial fluid of the tissues. They often attach to other cells part of the 
immune system, which have specific receptors for binding antibody molecules. 
Membrane associated and secreted antibodies differ slightly in constant region 
amino acid sequence. B cells are the only cells that can synthesise antibodies, 
where they can be found in the endoplasmic reticulum (ER) and Golgi complex. 
The heavy and light chains are synthesised on membrane bound ribosomes in the 
ER, where the formation of disulphide bonds takes place, covalently associating 
the chains into immunoglobulin molecules, and oligosaccharides are attached to 
the molecule (see section 1.7). The antibodies are then transferred into the Golgi 
complex, where modification of the carbohydrates takes place, and then to the 
plasma membrane in vesicles, where they are secreted or anchored to the cell 
membrane.
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Figure 1.5 Schematic o f an IgG
The molecule is built up o f four polypeptide chains; two heavy (H) and two light 
(L), held together by disulphide bonds between the cystein residues on the chains, 
one between the heavy and light chain and two connecting the two heavy chains. 
The light chains contain one constant region (C l) and one variable (ViJ region 
while the heavy chains contain three constant regions (ChL Ch2  and ChS) and 
one variable region (Vu). The hinge region is located between ChI and Ch2 and 
confers flexibility on the molecule. This is where the proteolytic enzyme papain 
can cleave the IgG into two parts that carry the antigen binding sites, Fab, and 
one crystallisable fragment, the Fc part.
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1.6.4 Half-antibodies
The IgG molecule is built up by two heavy and two light chains linked together by 
disulphide bonds. The heavy and light chains are synthesized separately and then 
assembled into the IgG tetramer structure H2L2 . Each light chain is built up by 
two domains that are created through two intrachain disulphide bonds between 
cystein residues, while each heavy chain is built up by four of these domains, 
through four intrachain disulphide bonds. One heavy and one light chain are then 
linked together aided by the heavy chain-binding ER chaperone of the HSP 70 
family, BiP (Lee et al, 1999). Lee describes how BiP interacts with the ChI 
domain, which remains unfolded in free heavy chains, until the light chain binds 
to the heavy chain and BiP is released and the CH1 domain folds into its correct 
conformation and the intact IgG molecule is obtained.
The subclasses of IgG (IgGl, IgG2, IgG3 and IgG4) mainly vary in the structure 
of the hinge region, where the disulphide bonds between the two heavy chains are 
situated. The structure of this region affects the flexibility of the molecule and this 
in turn has an effect on the ability of correct and stable interchain disulphide 
bonding. In IgG4 the covalently linked H2L2 tetramer, which is bound by two 
interchain disulphide bonds between the two heavy chains in addition to the 
disulphide bonds linking each light chain to a heavy chain (see Figure 1.5), is 
secreted together with a non-covalently linked tetrameric structure, which can 
disassociate into HL dimers (Angal et al, 1993; Bloom et al, 1997; Deng et al, 
2004; King et al, 1992; Zhang and Czupryn, 2002). These tetramers lack the 
interchain disulphide bonds in the hinge region between the two heavy chains and 
seem to be a general feature of the IgG4 subclass (King et al, 1992). The four 
subclasses have the same sequence CPXCP in the core hinge region, where X is 
proline in IgGl and IgG2, arginine in IgG3 and serine in IgG4 (Angal et al, 1993). 
The difference in structure and stability of the different subclasses was shown by 
Angal et al. (1993) and Bloom et al. (1997), who both substituted the serine of the 
IgG4 hinge region with that of a proline of the IgG 1/2 hinge region, which 
eliminated the presence of the half- mAb. The fact that the IgGl subclass does not 
experience these half-antibodies is probably one of the reasons that most approved 
mAbs are of this subclass.
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The mAb used in this research is an IgG4, serving as a model antibody, and will 
therefore be subject to the presence of HL dimers. These dimers may be 
undesirable in the production of mAbs for therapeutic purposes, unless they can 
stay non-covalently bound. There have been a few attempts in the literature to 
reduce their occurrence. The mAbs where dimers occur have been reported to 
contain a higher proportion of free sulphydryl groups than those only containing 
covalently bound intact tetramers (Chadeijian et al, 2005; Cromwell et al, 2006; 
Zhang and Czupryn, 2002). The presence of free sulfhydryl groups was reduced 
10-fold by Chaderjian et al. (2005) with the addition of copper sulfate, which 
creates an oxidative environment, facilitating the formation of disulphide bonds. 
Deng et al. (2004) took a more preventative approach that could be used during 
early product development. They developed a Westem-blot based screening 
method that could help identify the most promising clone with regards to HL 
dimers when screening for which cell line to use. In the research presented here, it 
was not attempted to minimise the HL dimers, but rather to note their presence, 
evaluated their structure and investigated the effect of processing conditions on 
the amount present.
1.6.5 Modifications of IgG
After the protein structure of the antibody has been synthesised, post-translational 
modifications take place. Some of these apply to a number of proteins in general, 
for example glycosylation (see section 1.7), while others are specific to 
mammalian cell culture or even to mAbs in particular. One example of a 
modification that is specific to proteins produced using mammalian cell culture is 
the proteolytic degradation of the C-terminal lysine residues (Figure 1.6). This has 
been observed during characterisation of numerous mAbs. To mention a few, one 
group showed the complete absence of the expected C-terminal lysine residue of a 
CD4-IgG hybrid (Harris et al, 1990), while Beck et al. (2005) detected similar 
data for a humanized recombinant mAb produced in NS0 cells with almost 
complete absence of C-terminal lysine, however in this case a more heterogeneous 
population was detected with 6% of the population still carrying a lysine residue 
on one of the two heavy chains and 2% with both lysines still intact. An even
41
Cecilia Reid Chapter 1
more heterogeneous population of a mAb was recorded (Santora et al, 1999) 
where approximately 70% of the antibodies had both lysines removed, 23% had 
one intact lysine and 7% still had both lysines intact. It has not been established 
when or where this modification takes place or even why, but it is of common 
knowledge that it does take place. The reaction is enzymatic by the action of a 
carboxypeptidase and is evident in culture produced mAbs as well as plasma 
derived mAbs (as reviewed by Harris, 1995).
Another commonly observed modification of mAbs is the cyclization of TV- 
terminal glutamine to pyroglutamic acid. Most IgG heavy chains have either a 
glutamine (Q) or a glutamic acid (E) residue at its TV-terminal, which can be 
converted into pyroglutamic acid (pE) with the loss of an amino group (Figure 1.7 
a and b). Studies show that this modification takes place at a high rate; a 70% 
conversion of Q to pE was detected during production as well as continued 
conversion after storage at 29°C for 3 months to almost complete conversion to pE 
(Rehder et al, 2006). It has been debated whether this process is enzymatic or 
spontaneous and whether it is a co-translational or post-translational modification, 
and the consensus seems to be that it could be all of these. Early studies indicated 
that the cyclization of glutamic acid is enzymatic rather than spontaneous 
(Twardzik and Peterkof, 1972). A study looked at the cyclization of glutamine on 
a peptide and showed that this reaction does occur spontaneously, but at a low rate 
under physiological conditions (Busby et al, 1987). They also identified the 
enzyme glutaminyl cyclase to carry out the conversion in vivo. In contrast to most 
reports, one group did not detect any pyroglutamic acid in their purified mAb, but 
noted conversions of up to 50% upon storage, with higher conversion rates at 
temperatures above 29°C and lower or higher pH (in the range pH 4-8, the 
minimum conversion was observed at pH 6) (Yu et al, 2006). From the mentioned 
studies it has become obvious that the conversion of glutamine to pyroglutamic 
acid takes place both during production and during storage and the final mAb 
product will be a heterogeneous population with one, none or two glutamine 
residues converted. While it seems the modification is more likely to take place 
than not, the effects it has on stability and bioactivity of the mAb are not entirely 
understood.
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Figure 1.6 C-terminal lysine cleavage
This shows a schematic o f  an IgG. The variable regions are shown in grey while 
the constant regions are shown in black. The lysine residues (K) at the C-terminal 
o f each o f the heavy chains have been marked out. These are prone to being 
cleaved o ff resulting in a mass shift o f  -128 Da per residue and a heterogeneous 
population where the IgG has none, one or two lysine residues.
Glutamine (Q) Pyroglutamic acid (pE)
Figure 1.7 Cyclization o f N-terminal glutamine
a) shows a schematic o f an IgG with the glutamine residues (Q) at the N-terminal 
o f each o f the heavy chains have been marked out. These can be converted to 
pyroglutamic acid (pE) by cyclization and the loss o f an amino group (NH3) (b), 
resulting in a mass shift o f  -17 Da per amino group, a total o f -34 Da.
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/ .  7 Glycosylation
Antibodies are glycoproteins, meaning they are proteins that have carbohydrates 
attached to them through the process of glycosylation. Glycoproteins can be found 
in cellular membranes, particularly the plasma membrane, and also in 
extracellular secretions such as plasma. Oligosaccharides are covalently attached 
to the amino acid side chains of the protein, which will have an impact on the 
three dimensional structure of the molecule. Glycosylation is of great importance 
not only to the structure, but also to the function of the protein, which is further 
discussed in section 1.7.4.
1.7.1 Glycan structures
Glycoprotein carbohydrate chains vary in structure and can therefore be divided 
into 2 major classes; TV-linked and O-linked. TV-linked can then be further divided 
into three classes; the complex type, the high-mannose type and the hybrid type. 
These subgroups share the common feature of linkage to the amino group of 
asparagine (Asn) while differing in the sugar components; the complex type 
consists of TV-acetylglucosamine (GlcNAc), mannose, galactose, fucose and sialic 
acid, the high-mannose type consists only of TV-acetylglucosamine and mannose 
and the hybrid type has features of both the two first mentioned (Figure 1.8). TV- 
linked glycosylation does not take place on every asparagine residue, but only at 
the recognition sequence Asn-X-Ser/Thr, where X can be any amino acid except 
proline. 0-linked oligosaccharides on the other hand, are linked to the hydroxyl 
groups of serine or threonine, the first sugar residue usually being TV- 
acetylglucosamine, and do not share a recognition sequence (Ashford and Platt, 
1999; Fukuda, 1994). A glycoprotein can contain both TV- and O-linked 
oligosaccharide chains at multiple sites, which together with the different 
monosaccharide combinations give rise to structural heterogeneity.
1.7.2 Glycan synthesis
The glycosylation reactions take place in the ER and in the Golgi vesicles. 
However, there is a difference in the biosynthesis of TV- and O-linked 
oligosaccharides. TV-linked glycosylation (Figure 1.9) is commenced in the lumen
44
Cecilia Reid Chapter 1
of the ER where first a lipid-linked oligosaccharide precursor is synthesised. This 
oligosaccharide, GlcNAc2Man9Glc3, linked to dolichol, is then transferred to an 
Asn residue on the nascent peptide chain. This is catalysed by 
oligosaccharyltransferase. From the newly synthesised glycoprotein the three 
glucose and one mannose residues are enzymatically cleaved off by ER a- 
glucosidase I and II and ER a-mannosidase respectively, and the folded protein is 
then exported from the ER. This process is aided by interactions with integral 
membrane proteins such as calnexin, which can bind to incompletely or 
incorrectly folded glycoproteins that will have a glucose residue reattached to it, 
preventing export, while refolding occurs, a-glucosidase II then cleaves off the 
remaining glucose residue and the corrected glycoprotein can be released and 
carried by vesicular transport from the ER to the Golgi Apparatus (GA). Here the 
oligosaccharide chain, Man8GlcNAc2, is attacked by Golgi a-mannosidase I, 
which cleaves off a further three mannose residues creating the precursor for 
oligosaccharides of the high-mannose type, which can then be further processed. 
This molecule also serves as a precursor for the other types of A-linked 
oligosaccharides; the enzyme A-acetylglucosaminyl transferase adds a GlcNAc to 
the structure to form the precursor for the hybrid type oligosaccharide. This 
molecule then also serves as a precursor for the complex type where Golgi a- 
mannosidase II cleaves off two mannose residues to form a molecule to which 
other monosaccharides can be added (Ashford and Platt, 1999; Fukuda, 1994). 
The further processing of the oligosaccharide chains varies from species to 
species. This creates a problem when producing biopharmaceutics that need to be 
properly glycosylated; the host cell usage is very restricted. As mentioned in 
section 1.1.1, this has prompted for usage of mammalian cell culture in order to 
achieve the correct glycosylation.
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Figure 1.8 Different subgroups o f N-linked oligosaccharide structures
(a) complex type, (b) hybrid type and (c) high-mannose type. The highlighted area 
shows the common pentasaccharide core o f two N-acetylglucoseamine and three 
mannose residues attached to the asparagines (Asn) in the recognition sequence 
Asn-X-Ser-Thr. The additions to the core structure are what separate the different 
types. The high-mannose type is only made up o f mannose residues in addition to 
the core while the complex type can have GlcNAc, galactose and sialic acid added 
to the mannose antennae, as well as a fucose residue attached to the Asn-linked 
GlcNAc residue. The hybrid type is a mix o f the two.
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Figure 1.9 Schematic o f N-linkedglycosylation
(Legend on following page)
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Figure 1.9 continued. The glycosylation sequence is commenced in the lumen o f  
the ER (above the broken line). The initial GlcNAc2Man9Glc3-oligosaccharide is 
synthesised while linked to a dolichol lipid. The glycan is then transferred to an 
Asn residue on the nascent peptide chain, catalysed by oligosaccharyltransferase. 
The three glucose residues are then enzymatically cleaved o ff by ER glucosidase I 
and II and one mannose residue is removed by ER mannosidase leaving a 
GlcNAc2Man8-oligosaccharide that can be exported from the ER to the Golgi by 
vesicular transport. In the Golgi three further mannose residues are cleaved off 
by Golgi mannosidase I, resulting in the GlcNAc2Man5 structure that is the 
precursor for the high-mannose type glycans where further mannose residues can 
be added. The GlcNAc2Man5 structure also serves as a precursor fo r  the other 
two types o f N-linked glycosylation; N-acetylglucosaminyl transferase adds a 
GlcNAc residue to create the GlcNAc3Man5 structure that can then be further 
processed as hybrid type glycans. The GlcNAc3Man5 structure in turn serves as a 
precursor for the complex type glycans when Golgi mannosidase II removes two 
mannose residues resulting in the GlcNAc3Man3 structure that can be further 
processed to obtain the different complex glycan structures.
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1.7.3 Glycosylation of IgG
It is now of general knowledge that IgG exhibits A-linked glycosylation at 
asparagine (Asn) 297 (Beck et al, 2005), situated in the CH2 domain. The glycan 
at this site is of the complex type (Figure 1.8) and can therefore contain GlcNAc, 
fucose, mannose, galactose and sialic acid. However, the heterogenic nature of 
glycosylation means that the glycans vary in composition from species to species 
(Raju et al, 2000; Saba et al, 2002), for example between human and mouse IgG 
(Hossler et al, 2006), and so cell line selection is therefore of importance when 
producing therapeutic antibodies. There is, however, a predominant structure 
found among all IgGs; core-fucosylated asialo biantennary chains with varying 
levels of galactosylation, with small amounts of monosialyl and afucosyl 
oligosaccharides present (Kunkel et al, 2000; Saba et al, 2002). Figure 1.10 shows 
a schematic explaining the nature of these glycan structures; they most often have 
a fucose attached to the core structure and can have none (GO), one (G l) or two 
(G2) galactose residues attached to the GlcNAc residues on the antennae, and to a 
lesser extent sialic acid attached to the galactose. The most commonly observed 
glycan structure in human IgG is FucGlcNAc2Man3GlcNAc2 (G0F) (Krapp et al, 
2003). The glycans in Figure 1.10 are the most commonly observed in IgG; 
however, other variants of these structures have also been reported. Bailey et al, 
2005, observed glycans where only one of the antennae was extended, generating 
structures like the examples shown in Figure 1.11. This has not been widely 
reported and so the frequency of their occurrence is most likely an exception 
rather than a rule. Up until recently most studies of glycosylation structures have 
involved a deglycosylation step to release the glycans from the peptide backbone 
in order to analyse separately. Using these methods it has been possible to map 
which glycans are present, but each IgG molecule has two glycan chains attached, 
one on each heavy chain, so the possibility of one IgG molecule having two 
different glycans attached was not commonly discussed. With the advancement of 
more powerful analytical techniques, the intact IgG can now be studied and it has
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Figure 1.10 Glycosylation o f  IgG
The predominant glycosylation structure in IgG has a fucose residue attached to 
the first GlcNAc residue o f the core structure common to all glycan types (dark 
grey-shaded area, with the exclusion o f the bisecting mannose in dotted line) and 
is o f a biantennary structure with one GlcNAc attached to each o f  the arms (light 
grey-shaded area) and with varying levels o f galactosylation (GO, G1 and G2). 
There can also be small amounts o f non-fucosylated glycans and glycans with 
sialic acid attached at the end o f the arms. The bisecting GlcNAc (dotted line) 
occurs naturally in 5-10% o f human IgG (Krapp et al, 2003), but is not commonly 
reported in studies.
Figure 1.11 Variations in glycosylation o f IgG
Bailey et al. (2005) reported some variations o f the commonly observed IgG 
glycosylation from analysing IgG2 glycans. They observed a biantennary 
structure where only one o f the antennae was extended as the examples in this 
figure; a) shows a GO structure with one GlcNAc missing, b) shows a GIF 
structure with one GlcNAc missing and c) shows a G2F structure with a GlcNAc 
missing, with both galactose residues added on to the same arm.
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become evident that two different glycans can be attached to the same IgG 
(Gadgil et al, 2006).
1.7.4 Effects of glycosylation
Glycosylation of IgG has proved to be essential for efficient activation of the 
response mechanisms associated with the Fc part (Lund et al, 1996; Mimura et al,
2000). It plays an important role in the recognition of the cellular receptors and 
complement. Studying the crystal structure of the IgGFc-FcyRIII complex shows 
that the interaction site on the IgG is the hinge proximal region of the Ch2 domain 
(Sondermann et al, 2001), indicating some importance of glycosylation. 
Interactions between amino acids of IgG (not Asn297) and sugar residues of its 
oligosaccharide chain and their influence on activity have also been investigated 
(Lund et al, 1996). Replacement of amino acid residues around Asn297 changed 
the interactions between the amino acid residues and the sugar molecules, which 
in turn changed the conformation of the hinge region. This resulted in decreased 
recognition of human chimeric IgG by guinea pig C, human C lq and human 
FcyRI. Another study relates glycosylation to biological activity and also 
structural stability (Mimura et al, 2000). Here truncated glycoforms were 
examined and an increase in stability and activity was observed compared to the 
deglycosylated form. Stability studies were also carried out by Krapp et al. 
(2003). Truncated glycoforms of IgG-Fc showed conformational changes in the 
Ch2 domain, which in turn affects the interaction with the cellular receptors. The 
effects of glycosylation on structure and stability have also been studied for other 
proteins. The thermostability of p-Lactoglobulin increased when the protein was 
modified through glycosylation (Broersen et al, 2004), although in this case the 
structural packing remained the same. These findings have lead to ideas of 
improving protein function and stability through glycoengineering. One group 
managed to improve stability and in vivo activity of three different proteins 
(recombinant human erythropoietin, leptin and Mpl ligand) by introducing 
recognition sequences for glycosylation before expression (Elliott et al, 2003).
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1.7.5 Factors affecting glycosylation
It has become obvious that glycosylation is a very important post-translational 
modification that confers important attributes to a glycoprotein and can affect 
efficacy and stability of the protein when used as a therapeutic. Glycosylation 
creates a heterogeneous product population, but how does the population change 
and what are the underlying factors? Already mentioned is that glycosylation is 
species-specific and so therefore will vary when using different cell lines. Several 
studies have also been carried out that show variations in glycosylation patterns 
with different culture methods and conditions; one group observed less sialylation 
and greater glycoform heterogeneity in human monoclonal IgM produced in 
mouse ascites compared to the IgM produced in-vitro in hollow-fibre perfusion or 
serum-free airlift cultures (Maiorella et al, 1993). Different levels of sialylation 
were also observed (Schweikart et al, 1999) when comparing the glycosylation 
patterns of murine monoclonal IgA produced in different cultivation systems 
(continuous stirred tank, fluidised bed and hollow fibre reactor). Again, Kunkel et 
al. (2000) noted variations in the relative amount of sialic acid residues when 
comparing a monoclonal IgGl produced in two different bioreactors (LH Series 
210 and New Brunswick Scientific CelliGen bioreactors). This group also found 
that different levels of dissolved oxygen (DO) concentrations affect the level of 
galactosylation with an increase in the relative amount of agalactosyl and a 
decrease in digalactosyl glycans at lower DO concentrations. One group observed 
higher levels of galactosylation in monoclonal IgG2 produced in static or spinner 
flasks compared to in ascites or a hollow-fibre system and that the influence of 
media content (protein free, low serum or high serum content) is more prominent 
in high cell-yield culture systems (Cabrera et al, 2005). The influence of media 
content was also studied (Serrato et al, 2007) when serum free and chemically 
defined media was observed to increase cell concentration and mAb titre but 
caused decreased sialylation and increased fucosylation as compared to a 
traditional serum-containing medium. They also observed lower levels of 
galactosylation with increased relative amounts of the GO glycan in the IgGl from 
serum free medium; however, this culture also displayed an increase in 
extracellular /?-galactosidase activity, which could explain this observation. From 
the above-mentioned studies it becomes obvious that a greater understanding of
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the effects of different factors during cell culture on glycosylation patterns is 
being obtained, but is a constantly ongoing process. What have not received a lot 
of attention up to date are the effects that further processing and purification could 
have on glycan structures.
1.7.6 Glycoengineering and current trends
One of the main problems associated with the use of murine Abs for therapeutic 
purposes is the fact that there are differences between for example mouse Abs and 
human Abs and the immunogenic responses these can cause. Although there are 
still some murine mAbs on the market, Zevalin being one of them, they are a 
minority. Today, the trend is to create mAbs by genetic engineering to create 
recombinant proteins (Dillon et al, 2004; Fotinopoulou et al, 2003; Wan et al,
2001). This ensures production of proteins that suit the purpose and more 
importantly, it ensures safety and efficiency of the immunisation, preventing an 
immune response upon injection of a foreign protein. In addition to the murine 
mAbs on the market, there are a few chimeric mAbs, i.e. with a murine variable 
region and a human constant region, for example Erbitux and Rituxan, and a 
couple of fully human mAbs, Humira (Abbott Laboratories, Abbott Park, IL) 
treating inflammatory diseases and Vectibix (Amgen Inc., Thousand Oaks, CA) 
for colorectal cancer. All other mAbs that are approved for therapeutic purposes 
are so called humanised, where murine hypervariable regions are introduced into 
human Abs, resulting in an almost entirely human Ab to keep the immunogenic 
response to a minimum.
Mammalian cells are currently the main means of producing therapeutic proteins 
and mAbs in particular. The main reason behind this is the glycosylation pattern 
produced by the cells that is most similar to human glycosylation, compared to 
bacteria, yeast or fungi. The mammalian cell system is the most appropriate one, 
but it is not perfect in this respect. One of the problems associated with 
therapeutic protein production using murine cell lines is the occurrence of the 
sialic acid N-glycolylneuraminic acid (Neu5Gc), which is absent in human Abs 
(Varki, 2001) and can therefore cause immunogenicity. The discrepancies in 
glycosylation patterns have led to in vivo engineering of the glycosylation
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pathways and also N-glycan remodelling in vitro. One of the problems associated 
with mAbs is the high dosages required due to their relatively low activity in vivo. 
It has been shown that the ADCC activity can be increased through 
glycoengineering, especially non-fucosylated variants of IgG have shown 
improved efficiency. One group found that cytotoxicity was enhanced by the lack 
of core-fucosylation, with a 50-fold increase in binding to FcyRIIIA (Shields et al,
2002). Recently another group (Nechansky et al, 2007) found that a de- 
fucosylated IgGl not only showed higher in vitro activity than the fucosylated 
native mAb, but also showed no inhibition from a high concentration of 
endogeneous IgG in serum, which is normally the cause of the lower in vivo 
activity due to competition of binding to FcyRIII on the effector cells. It is not 
only the core-fucose that has an affect on ADCC. One group found that in vitro 
remodelled mAbs (Rituxan and Herceptin), with a high content of bisecting 
GlcNAc, showed a 10-fold increase in ADCC activity, while on the other hand 
CDC stayed essentially unaffected (Hodoniczky et al, 2005).
Glycoengineering is not only a useful tool for mAbs, it can also improve the 
efficiency of other therapeutic proteins. Elliott et al. (2003) recorded increased 
activity and half-life of glycoengineered recombinant human erythropoietin, 
which normally have three N-glycosylation sites, Mpl ligand, which normally 
only has O-linked glycosylation, and leptin, which is normally absent of any 
glycans.
The glycoengineering concept has also opened up new opportunities in cell line 
selection; monoclonal antibodies with human glycosylation structures, rather than 
their ordinary high-mannose type of N-glycosylation, have been successfully 
expressed in yeast strains, such as Pichia Pastoris (Li et al, 2006). This has been 
achieved by complex engineering of the glycosylation pathways, as reviewed by 
Hamilton and Gemgross, 2007 and opens up possibilities of using a high-yielding 
well-known expression system.
From the above mentioned findings and many others with them, it has become 
obvious that glycoengineering, either in vivo through cell engineering or in vitro 
by glycan remodelling, can be a powerful way of improving the efficiency of
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mAbs. An increased in vivo activity can in turn decrease the dose required for 
treatment. It can also increase the half-life of the mAh so that the frequency of 
administration can be reduced. Glycoengineering has been the focus of many 
studies over the last few years and will most likely be a feature of future mAb 
production.
1.8 Protein analysis
It is of vital importance that proteins to be used therapeutically maintain their 
biological structure in order to function properly. During production and 
processing the product will be exposed to unfavourable and sometimes harsh 
conditions that can alter the structure or lead to other unwanted product versions, 
such as aggregates. In order to achieve pure clinical products and to ensure 
consistency from batch to batch, careful monitoring is required. There is a vast 
array of analytical techniques available for protein analysis, with the possibility to 
obtain a range of information regarding concentration, structure, conformation 
and function. Not all of these techniques can be applied or are useful at any stage. 
Some techniques can only give one piece of information, for example the 
molecular weight, while others give more. Careful consideration has to be taken to 
map the pieces together, obtain all the necessary information at any given stage 
and not bypass any important aspects. Another way to vary the analysis is to use 
enzymatic digestion. This will cleave the protein into smaller fragments where for 
certain applications some can be discarded and others further analysed to collect 
more specific data. There are a few enzymes that are used in this area. First there 
are the two already mentioned regarding the IgG molecule (see section 1.6.3); 
papain, cleaving IgG into Fc and the two Fab fragments, and pepsin, cleaving into 
several parts of the Fc fragment and the F(ab’)2 fragment. Another enzyme that 
can be used is trypsin (Jung et al, 2005; Yang and Hancock, 2004). Trypsin 
cleaves proteins C-terminally of lysine and arginine with a relatively high 
specificity and results in a number of smaller peptides that can be analysed with 
better resolution. If the interest lies in glycosylation of the protein, release of the 
oligosaccharide chains can be carried out using endo- or exoglycosidases that 
cleave internal glycosidic bonds or cleave monosaccharides from the non­
reducing end of the oligosaccharide respectively. The glycans can then be further
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analysed using advanced techniques such as matrix-assisted laser 
desorption/ionisation mass spectrometry (MALDI-MS) (Colangelo and Orlando,
2001). Here follows an overview of some of the different techniques available and 
their possible uses in monitoring protein structure during processing. Not all of 
these techniques have been utilised in the research presented here, instead some of 
them have been selected to cover the areas of interest.
1.8.1 Electrophoresis
Gel electrophoresis is a simple method for protein analysis and is the most widely 
used in research. Gels can be made up of agarose or polyacrylamide, depending 
on the application and they can be of constant or gradient concentration depending 
on resolution required. Other attributes to use in the gel is a pH gradient (as in 
isoelectric focusing) or addition of sodium dodecyl sulphate (as in SDS-PAGE). 
This provides a variation in the technique where proteins can be separated on a 
different basis, for example size (mass) or electric charge.
1.8.1.1 SDS-PAGE
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is the 
most widely used technique for qualitative analysis of proteins. SDS is an anionic 
detergent that denatures proteins by binding to the backbone structure and 
conferring a negative charge on the protein relative to the length of the 
polypeptide. SDS is often combined with a reducing agent, for example P- 
mercaptoethanol or dithiothreitol) and then used for a polyacrylamide gel that will 
separate proteins according to size. This method can be used to determine the 
molecular weight of a protein or to investigate the purity of a sample. It is a basic, 
very simple technique, but is not very sensitive so different glycoforms would not 
be separated. However, it can be useful when looking at different proteins (Yang 
and Hancock, 2004) or when looking at aggregation or heavy and light chain 
complexes of incompletely assembled antibodies.
1.8.1.2 Isoelectric focusing
Isoelectric focusing (IEF) is an electrophoresis technique that separates proteins 
according to their isoelectric points (pis) and not their size as with SDS-PAGE.
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The technique utilises a gel (usually polyacrylamide, but agarose can also be 
used) with a pH gradient. The gel contains carrier ampholytes that when an 
electric field is applied, arrange themselves according to pi from the anode to the 
cathode, creating a pH gradient. The protein sample is applied and migrates 
through the gel according to its charge until it reaches the pH that corresponds to 
its pi, where its net charge is zero. This results in proteins being separated on the 
basis of charge.
1.8.1.3 2D-gels
Gels can also be used for two-dimensional analysis. The technique provides the 
possibility to analyse proteins and polypeptides in complex sample mixtures. This 
approach combines separation according to charge through IEF with separation on 
the basis of size by SDS-PAGE. First the sample mixture is loaded onto an IEF 
gel, which is run as normal. The first gel is then loaded onto the top surface of the 
second SDS gel. Here a gel with either a constant or a gradient polyacrylamide 
concentration can be used, depending on the desired resolution (Hanash, 1998). 
SDS-PAGE is carried out and the gel is then stained, usually by silver-staining, in 
order to reveal the separated proteins and to interpret the gel. 2D gels can be used 
for comparing proteins from cells, tissues or body fluids and provides the 
possibility of direct sequencing of glycan structures from the gels (Rudd and 
Dwek, 1997). This provides usefulness in the monitoring of glycosylation patterns 
during production and processing of therapeutic glycoproteins and could detect 
possible modifications.
1.8.2 ELISA
Immunoaffinity measurements are another way to analyse proteins. These utilise 
the fact that for example antibodies have affinity for other proteins and bind to 
them accordingly. The affinities will be stronger or weaker depending on the 
structure of the protein and can therefore be used to detect modifications, or 
combined with for example a colourimetric detection method it can be used for 
concentration measurements. The enzyme-linked immunosorbent assay (ELISA) 
is a technique widely used in protein analysis. It can be used for all molecules to 
which an antibody can bind and provides a way of quantification as well as
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detection. There are two basic types of ELISA; direct and indirect, with the latter 
being the most commonly used, providing high sensitivity and specificity. This 
method utilises two antibodies binding to different parts of the protein to be 
analysed. The primary antibody is first coated onto a solid phase and then the 
sample is applied and left for incubation. The excess is washed off and a 
secondary antibody is added. This antibody binds to a different part of the sample 
and is labelled with for example horseradish peroxidase. The excess secondary 
antibody is washed off and a substrate is added, the response usually being 
detected colourimetrically.
1.8.3 Chromatography
1.8.3.1 Protein A/G affinity chromatography
Protein A/G affinity chromatography is used for antibody purification (see section 
1.2) but can also be used as an analytical method when measuring antibody 
concentration and is often the method of choice for monitoring product formation 
during cell culture. As mentioned, protein A/G affinity chromatography is highly 
specific and will therefore bind to and extract antibodies exclusively, eliminating 
any other proteins and will therefore give a very accurate measure of the antibody 
concentration through absorbance measurements at 280 nm. Due to the different 
binding characteristics of protein A and protein G (Aybay, 2003), protein A is 
normally used for intact antibodies while protein G is more suitable for antibody 
fragments such as Fab.
1.8.3.2 Lectin affinity chromatography
Affinity chromatography of antibodies, or any glycoproteins for that matter, can 
also be carried out using lectins. Lectins are proteins that bind carbohydrates and 
therefore glycoproteins. They are widely found in nature and can be extracted for 
example from plants like Trichosanthes dioica (Sultan et al, 2004), or animals like 
the snail Cepaea hortensis (Gerlach et al, 2005). Different lectins have different 
saccharide specificities; the first mentioned being Gal/GalNAc specific while the 
latter is GalNAc/GlcNAc specific. Lectins can be used both as a 
purification/separation technique (Demelbauer et al, 2005; Yang and Hancock, 
2004) and in analytical methods (Fotinopoulou et al, 2003; Jankovic and
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Kosanovic, 2005b). One group used a multi-lectin column where lectins were 
bound to agarose that was then packed in a chromatography column to monitor 
changes in glycosylation patterns by use of displacers specific to the lectins in the 
column (Yang and Hancock, 2005). The isolated glycopeptides can be analysed 
further by LC-MS/MS in this case, or other advanced analytical techniques such 
as MALDI-TOF (Demelbauer et al, 2005) or the elution profiles can be used on 
their own (Jankovic and Kosanovic, 2005a). Lectins can also be used in other 
analytical techniques than chromatography, for example surface plasmon 
resonance (SPR) and ELISA (see section 1.8.2) and can be a useful tool in 
oligosaccharide profiling during production of monoclonal antibodies 
(Fotinopoulou et al, 2003).
1.8.3.3 Size Exclusion Chromatography
Size exclusion chromatography (SEC) is a technique that separates molecules on 
the basis of size. The technique utilises a semi-permeable polymeric gel, into 
which smaller molecules can enter, while larger ones can not and will therefore go 
straight through the column and elute first. SEC is widely used for protein 
purification but is also a valuable analytical technique. It can be used for 
identification and quantification of proteins, as well as for quality control. It is a 
useful tool for detecting product variants, such as aggregates.
1.8.3.4 HPLC
High-performance (or high-pressure) chromatography (HPLC) is widely used in 
biotechnology to separate protein mixtures. As the name indicates the technique 
utilises high pressures to achieve very high resolution that can separate for 
example peptides of similar size and charge. For the purpose of protein separation, 
HPLC is mainly used in reversed phase. A non-polar stationary phase is used 
together with a moderately polar aqueous mobile phase. The analytes will be 
retained in the column and then eluted by adding a less polar mobile phase, most 
often acetonitrile or methanol, according to the hydrophobicity of the analytes. 
Trifluoroacetic acid or formic acid can be added to the mobile phase to aid 
separation. HPLC can be used for purification purposes, but is mainly used as an
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analytical technique, where it is sometimes coupled to mass spectrometry (see 
section 1.8.4.1), but can also be used as a stand-alone method.
1.8.4 Mass spectrometry
Mass spectrometry (MS) is a high-throughput system that offers rapid protein and 
peptide analysis with extremely high sensitivity. During the last couple of decades 
the development of so called soft ionisation techniques, such as electrospray 
ionisation (ESI) and matrix-assisted laser desorption/ionisation (MALDI) has 
made MS a more and more popular technique. It shows great usefulness in the 
analysis of glycoproteins (Dell and Morris, 2001) and can analyse intact 
molecules or peptides. All MS techniques work on the same general basis; a 
detector measures the mass to charge ratio (m/z) of an ionised sample. Mass is 
given in Daltons and the fundamental unit for charge (the charge of an electron) is 
used. The way ionisation is achieved is generally what differs in the different 
methods, as already mentioned.
1.8.4.1 LC/ESI-MS
In ESI-MS, the liquid sample is introduced into the ion source through a capillary 
to which voltages are applied, and also to a counterelectrode and the focusing 
optics, resulting in an aerosol. These highly charged microdroplets travel until 
they hit the drying gas where they transform into gaseous ions. These ions have a 
charge distribution that is proportional to the number of ionisable groups in the 
analyte. ESI-MS is a popular tool for analysis of glycoproteins.( It is extremely 
sensitive and can pick up structural changes such as deamidation Hagmann et al,
1998) when used with data from other analytical techniques (in this case IEF).
Samples can be injected directly into the mass spectrometer or, more commonly; 
it can be coupled with liquid chromatography (LC). LC-MS can for example be 
used for characterisation of intact recombinant antibodies and to study their 
heterogeneity (Dillon et al, 2004; Le and Bondarenko, 2005) and for qualitative 
characterisation of glycans (Saba et al, 2002). LC-MS can also be used for peptide 
mapping and has been of use for localisation of the glycosylation site (Hagmann 
et al. 1998) when comparing therapeutic proteins and their glycosylation patterns
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(Ohta et al, 2002) and for characterisation and comparison of variants of 
recombinant proteins (Jung et al, 2005). LC-ESI-MS can also detect heterogeneity 
due to incomplete proteolysis or the modification of an amino acid (Stimson et al,
1999). RP-HPLC-ESI-MS was used by Wan et al. (2001) in the development of a 
method to investigate the heterogeneity in glycosylation of a recombinant 
antibody and the quantification of the different glycoforms. The HPLC was used 
to desalt and purify the samples and to separate heavy and light chain fragments. 
The sensitivity of the equipment also provides efficient analysis at low 
concentrations; only picomoles are required for good detection (Carr et al, 1993).
Mass spectrometry can also be utilised in tandem, i.e. MS/MS. The sample is 
analysed by MS, specific ions are then isolated and another round of MS is carried 
out. This technique provides a way of sequencing, confirming the primary 
structure that can be deduced from the first MS analysis (Demelbauer et al, 2005; 
Jung et al, 2005). LC-MS/MS can be used to specifically and selectively identify 
glycopeptides (Carr et al, 1993) and for structural analysis and assignment of 
isomers (Kawasaki et al, 2000).
1.8.4.2 MALDI-TOF
The technique of laser desorption (LD) has been around for several decades, but it 
was only in the late eighties that development of MALDI took place (Karas et al, 
1985). The basis of LD is that ions are produced by irradiating the sample with a 
high-intensity laser pulse. MALDI makes use of a matrix and is therefore 
applicable to proteins of a much higher molecular weight than LD. The matrix has 
to be volatile, e.g. 2,5-dihydroxybenzoic acid (Saba et al, 2002) or 2,4,6- 
trihydroxyacetophenon (Demelbauer et al, 2005) and is applied to the sample 
plate together with the sample and then dried. When the laser beam hits the solid 
sample preparation the matrix helps to excite the analyte molecules and then 
evaporates leaving the ionised molecule travelling to the detector in a time 
depending on its m/z ratio, hence the name MALDI-TOF (time-of-flight). This 
technique can be used to study glycosylation patterns in proteins and becomes 
very effective and specific when applied after release of glycans by glycosidases, 
as already mentioned (Colangelo and Orlando, 2001). MALDI is also suitable for 
semiquantification since the peak height or area is proportional to the amount of
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carbohydrate in the sample (Saba et al, 2002). However, it is pointed out that if 
this technique is to be used for quantification, careful consideration has to be 
taken to the chemical properties of the analytes in the sample mixture, since 
oligosaccharides differing with certain monosaccharides in structure will have 
different ionisation efficiencies.
1.8.4.3 SELDI-MS
As mentioned, the use of MS has proved very successful for detailed analysis of 
biological compounds. However, when analysing samples from complex biologic 
materials, these often contain many different molecules and a high degree of salts, 
so there is a need for time-consuming and labour-intensive purification methods 
such as centrifugation, filtration or liquid chromatography due to the sensitivity of 
the MS equipment. Recent advances in surface-enhanced laser 
desorption/ionisation (SELDI) offers the possibility to bypass extensive sample 
preparation. As the name suggests, SELDI works on the same basic principles as 
MALDI; a laser beam provides the energy to ionise analytes from a solid sample 
on a sample plate. However, in SELDI, the surface plays an important role in the 
extraction of the analyte. For further details see review by Merchant and 
Weinberger, 2000. Commercially, SELDI is provided by Ciphergen’s 
ProteinChip® Array System. The chips exhibit chromatographic capacity with 
binding on different basis: IMAC (immobilised metal affinity capture), ionic, 
reversed phase or hydrophobic or normal phase. A sample is applied to each one 
of the spots on the array and then washed with different buffers in order to 
facilitate the isolation of the analyte. This in situ technique provides the advantage 
of minimised sample loss when only small amounts are available. It also provides 
the possibility of working with relatively impure samples from various stages of 
the process of production and purification of therapeutic proteins.
1.8.4.4 ESI-TOF
Above are detailed some of the most commonly used mass spectrometry methods. 
These are by no means all of them and there are many variations on the basic 
techniques where different manufacturers combine different ionisation techniques
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with different detectors. One example is electrospray ionisation coupled with a 
time-of-flight detector (ESI-TOF). This is the technique we used in the studies 
presented here, since it allows for analysis of the intact mAb. The principles of 
this technique are outlined in Figure 1.12.
1.9 Aim
The aim of the research carried out was to develop a combination of experimental 
techniques and protocols with the ultimate output of a tool-kit for in-process 
determination of structure and conformation of biopharmaceuticals such as mAbs.
1.10 Objectives
In order to reach the aim of the research a series of concerns around the 
production and purification of therapeutic proteins, such as mAbs, were raised 
that needed investigation:
• Would the method of harvesting impact the detailed structure of the mAb?
• Would there be any knock-on effects on the subsequent purification process 
due to intracellular material released due to shear?
• Are there other parameters during harvest that could impact the mAb 
structure, e.g. holding time and temperature?
• Is it possible to use at-line monitoring of mAb structure, providing results in 
hours instead of days?
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Figure 1.12 Basic schematic o f ESI-TOF
The sample is introduced into a capillary that is situated inside the electrospray 
source. A high voltage is applied across the capillary resulting in the sample 
transforming into highly charged droplets that leave the capillary nozzle. Around 
the capillary is the nitrogen nebulising gas, which helps direct the emerging spray 
towards the analyser. At the end o f the nozzle, the nitrogen drying gas is applied. 
This aids solvent evaporation o f  the droplets so that single ions evaporate from  
the droplets and can be introduced into the analyser that is kept under high 
vacuum. The vacuum is applied to avoid any interference o f  the flight path by air. 
The ions then travel through the flight tube and are sorted according to their 
mass-to-charge ratio. The heavier the ion, the longer it will take to reach the 
detector.
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2 Materials and Methods
All reagents used were purchased from Sigma-Aldrich (Dorset, England) unless 
otherwise stated.
2.1 Cell culture
GS-CHO cells producing a chimeric IgG4 monoclonal antibody B72.3 were 
rcultured in a fed-batch, 10L airlift vessel, working volume 8.5 L, at 37°C and pH 
6.7-7.0. To monitor growth, cell count and viability were measured using a Vi- 
CELL™ (Beckman Coulter, Inc., Fullerton, CA, USA) while product formation 
was measured using protein A affinity chromatography. Three separate 
fermentations were carried out, providing samples for the different studies as 
indicated in results chapters.
2.2 Centrifugation for clarification
Samples were centrifuged (Eppendorf 581 OR, Eppendorf, Cambridge, UK) at 200 
x g for 20 min to separate cells from the product-containing supernatant. The 
supernatant was filtered through a 0.45 pm syringe filter (Low Protein Binding 
Durapore®, PVDF, Millipore, Co. Cork, Ireland) before storage at -20°C until 
further analysis. Cells were washed in PBS, centrifuged again at 200 x g for 10 
min, liquid discarded and cells then stored at -80°C until further processing. 
Samples that were sheared (see section 2.3) before clarification were centrifuged 
at 3,200 x g for 40 min in order to achieve sufficient separation.
2.3 Shear
For the purpose of studying the effect of shear during the first clarification step 
after fermentation, a USD shear device was used (Levy et al, 1999). The device 
consists of a stainless steel chamber 12 mm high with a diameter of 50 mm and 
inside it a 1mm thick rotating disc of diameter 40 mm. The sample volume used 
was 20 mL and the standard conditions of shearing at 15,000 rpm for 30 s were 
used except where stated otherwise. When studying the effect of different 
shearing conditions the following four sets of conditions were used; control with 
no shear, 15,000 rpm for 30 s, 15,000 rpm for 90 s, and 20,000 rpm for 30 s. The
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tip speed can be related to the maximum energy dissipation rate experienced, with
15,000 rpm corresponding to a maximum energy dissipation rate in the region of 
106 W kg'1 and 20,000 rpm corresponds to 107 W kg'1. Various maximum energy 
dissipation rates and their corresponding large-scale centrifuge are listed in Table 
2.1, where it can be seen that the former of the two shear rates chosen corresponds 
to the shear experienced in a larg-scale multichamber-bowl centrifuge under non- 
flooded conditions. The faster tip speed was chosen to investigate the impact of 
even higher energy dissipation rates to examine the effects of more extreme shear 
on the protein structure and conformation. In order to study the effect of shear on 
both the broth and the pure antibody in solution, some samples were sheared 
before centrifugation and some after as will be explained further at a later stage.
2.4 Holding
When studying the effects of holding time and conditions in between stages, 
samples of broth were held in 50 mL centrifuge tubes at two different 
temperatures; +4°C and +37°C. Samples were then removed at certain times; 0, 2 
h, 4 h and 24 h, clarified as above (see section 2.2) and then purified using protein 
A affinity chromatography or sheared as described previously (see section 2.3) 
and then clarified and purified.
2.5 Disruption of cells for purification of intracellular material
Cells were resuspended in PBS pH 7.4 after thawing. They were disrupted using a 
Lab 40 high-pressure homogeniser (Gaulin Micron Lab40, APV Gaulin, Lubeck, 
Germany) for complete release and then centrifuged (GS-6R centrifuge, Beckman 
Coulter) at 6,400 x g for 45 min. The debris was discarded and the mAb 
containing supernatant was filtered (0.45pm Durapore, Millipore) and then 
purified using protein A chromatography.
2.6 Protein A affinity chromatography for purification
Both intra- and extracellular material was purified using protein A affinity 
chromatography. A 1 mL HiTrap rProteinA Fast Flow column (GE Healthcare 
UK Ltd, Buckinghamshire, England) was used together with an AKTA™explorer 
system and UNICORN™ software (both GE Healthcare). A sample (10 mL of
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Maximum energy 
dissipation rate 
(W kg ')
Large-scale equivalent
2 x 105 Disc stack centrifuge operated at 15-80 L/hr and at 165 rps
6 x 10s
Multichamber-bowl centrifuge under flooded conditions, 
operated at 22 L/hr and at 167 rps
12 x 105
Multichamber-bowl centrifuge under non-flooded 
conditions, operated at 22 L/hr and at 167 rps
14 x 105 CARR Powerfuge™ operated at 20 L.hr and at 255 rps
Table 2.1 Maximum energy dissipation rates o f large-scale centrifuges
The above table shows the maximum energy dissipation rate experienced in 
various large-scale centrifuges (Boychyn et al, 2004). The values described in the 
right hand column represent the flow  rates and the bowl rotational speeds o f  the 
centrifuges.
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supernatant or 20 mL of clarified homogenised cells) was loaded onto the column 
using 10 mM PBS, pH 7.4, at a flow rate of 1 mL/min. Non-binding material was 
washed off using five column volumes of loading buffer and gradient elution then 
carried out with 10 mM sodium citrate, pH 3, from 0 to 100 % over 15 min. The 
eluted material was collected and immediately neutralised by the addition of 1M 
Tris, pH 9 and protein concentration measured by absorbance at 280 nm (Genesys 
lOvis, Thermo Scientific, Waltham, MA, USA). Samples were then diluted with 
0.1 M sodium acetate, pH 6.4, to a concentration of ~1 mg/mL.
2.7 Sample modification
2.7.1 Deglycosylation
For deglycosylation of the mAb, a denaturation step was first carried out by 
addition of 0.2% SDS in 100 mM mercaptoethanol to the protein solution (1 
mg/ml), which was then heated to 100°C for 10 min. After the denaturation step 4 
units of PNGase F in 5mM potassium phosphate, pH 7.5, was added to the protein 
solution and kept at 37°C overnight.
2.8 Antibody profiling by gel electrophoresis
2.8.1 Lab-on-a-chip
Samples were analysed using an Agilent 2100 bioanalyzer (Agilent Technologies, 
Santa Clara, CA, USA), protein 200 assay, non-reducing conditions, following 
manufacturer’s recommendations. The bioanalyzer is a lab-on-a-chip technology 
separating proteins on the basis of molecular weight.
2.9 Mass spectrometry
For detailed analysis of the molecular structure of the mAb, as well as the overall 
composition of the product stream, HPLC coupled to electrospray-time-of-flight 
mass spectrometry (ESI-TOF) was used.
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2.9.1 LC/MSD-TOF
For analysis of intact mAbs, LC/MSD-TOF (Agilent Technologies) was used. A 
Poroshell 300-SB C l8 reverse phase column (75 mm x 1 mm i.d., 5 pm pore size, 
Agilent Technologies) was injected for online desalting with 2 pL sample at 1 
pg/pL, heated to 70°C and the product eluted using a gradient starting at 5 % 
(v/v) acetonitrile in 5 % (v/v) formic acid in water rising to 95 % over 10 min 
with a flow rate of 200 pL/min. Proteins eluting from the column were ionised by 
an electrospray source, and the ions were analysed using a time-of-flight mass 
spectrometer. For the samples from the first fermentation, the drying gas 
temperature was set to 300°C at 8L/min. The protocol was reviewed and further 
optimised for the samples from the second and third fermentation in order to 
minimise noise levels and to allow for a deeper analysis. Therefore the gas 
temperature was increased to 350°C at 11 L/min. Agilent BioConfirm Software 
(Version A.02.00) was used for deconvolution of spectra. The deconvolution was 
carried out using the following parameters; step mass 1 Da, signal-to-noise 
threshold 5, isotope width 30 Da, and average mass 50 % of the peak.
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3 Structural analysis of IgG
3.1 Basic structure and sequence
The subject of this research was a monoclonal immunoglobulin G4 (IgG4). The 
IgG molecule is built up of two heavy and two light chains linked together by 
disulphide bonds. This structure forms the basis of the molecular weight, which 
depends on the amino acid composition. The amino acid sequence is translated 
from the mRNA that has in turn been transcribed from the DNA nucleotide 
sequences of the heavy and light chains (Figure 3.1 and Figure 3.2 respectively). 
The sequence is made up of the nucleotides adenosine (A), cytosine (C), guanine 
(G) and thymine (T) (uracil (U) in the case of RNA). Three nucleotides together 
form a codon, which is transcribed and translated into an amino acid.
Figure 3.3 and Figure 3.4 show the translated amino acid sequence for the heavy 
and light chain respectively. The signal sequence has been cleaved off and the 
stop codon is no longer included so that the first and last amino acids of the heavy 
chain are glutamine and lysine respectively and of the light chain are aspartic acid 
and cystein.
3.2 Modifications
After the protein back bone of IgG has been formed, post-translational 
modifications take place, the main one being glycosylation (see section 1.7). IgG 
has one site of TV-linked glycosylation at asparagine 297 on each of the heavy 
chains. The glycosylation is of the complex type and can therefore contain all or 
some of the following monosaccharides; TV-acetylglucosamine, mannose, glucose, 
galactose, fucose and sialic acid (TV-acetylneuraminic acid). The structure is most 
commonly of a core-fucosylated biantennary structure as can be seen in Figure 
3.5. Each finished glycan structure is built up of several monosaccharides; each of 
which contributes different masses (Table 3.1) to the basic molecular weight of 
the IgG creating a heterogeneous population.
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ATGGAATGGA GCTGGGTCTT TCTCTTCTTC CTGTCAGTAA CTACAGGTGT
CCACTCCCAG GTTCAGCTGC AGCAGTCTGA CGCTGAGTTG GTGAAACCTG 
GGGCTTCAGT GAAGATATCC TGCAAGGCTT CTGGCTACAC CTTCACTGAC 
CATGCTATTC ACTGGGCGAA GCAGAAGCCT GAACAGGGCC TGGAATGGAT 
TGGATATATT TCTCCCGGAA ATGATGATAT TAAGTACAAT GAGAAGTTCA 
AGGGCAAGGC CACACTGACT GCAGACAAAT CCTCCAGCAC TGCCTACATG 
CAGCTCAACA GCCTGACATC TGAGGATTCT GCAGTGTATT TCTGTAAAAG 
ATCGTACTAC GGCCACTGGG GCCAAGGCAC CACTCTCACA GTCTCCTCAG 
CCTCCACCAA GGGCCCATCC GTCTTCCCCC TGGCGCCCTG CTCCAGGAGC 
ACCTCCGAGA GCACAGCCGC CCTGGGCTGC CTGGTCAAGG A CTACTTCCC 
CGAACCGGTG ACGGTGTCGT GGAACTCAGG CGCCCTGACC AGCGGCGTGC 
ACACCTTCCC GGCTGTCCTA CAGTCCTCAG GACTCTACTC CCTCAGCAGC 
GTGGTGACCG TGCCCTCCAG CAGCTTGGGC ACGAAGACCT ACACCTGCAA 
CGTAGATCAC AAGCCCAGCA ACACCAAGGT GGACAAGAGA GTTGAGTCCA 
AATATGGTCC CCCATGCCCA TCATGCCCAG CACCTGAGTT CCTGGGGGGA 
CCATCAGTCT TCCTGTTCCC CCCAAAACCC AAGGACACTC TCATGATCTC 
CCGGACCCCT GAGGTCACGT GCGTGGTGGT GGACGTGAGC CAGGAAGACC 
CCGAGGTCCA GTTCAACTGG TACGTGGATG GCGTGGAGGT GCATAATGCC 
AAGACAAAGC CGCGGGAGGA GCAGTTCAAC AGCACGTACC GTGTGGTCAG 
CGTCCTCACC GTCCTGCACC AGGACTGGCT GAACGGCAAG GAGTACAAGT 
GCAAGGTCTC CAACAAAGGC CTCCCGTCCT CCATCGAGAA AACCATCTCC 
AAAGCCAAAG GGCAGCCCCG AGAGCCACAG GTGTACACCC TGCCCCCATC 
CCAGGAGGAG ATGACCAAGA ACCAGGTCAG CCTGACCTGC CTGGTCAAAG 
GCTTCTACCC CAGCGACATC GCCGTGGAGT GGGAGAGCAA TGGGCAGCCG 
GAGAACAACT ACAAGACCAC GCCTCCCGTG CTGGACTCCG ACGGCTCCTT 
CTTCCTCTAC AGCAGGCTAA CCGTGGACAA GAGCAGGTGG CAGGAGGGGA 
ATGTCTTCTC ATGCTCCGTG ATGCATGAGG CTCTGCACAA CCACTACACA 
CAGAAGAGCC TCTCCCTGTC TCTGGGTAAA TGA
Figure 3.1 Nucleotide sequence o f the cB72.3 heavy chain
A; adenosine, C; cytosine, G; guanine, T; thymine. The sequence begins with the 
start codon ATG, which is part o f  the 57 nucleotide long signal sequence. This is 
the highlighted region, which is later cleaved o ff so that the first amino acid is 
glutamine (Q) from the CAG codon and the last amino acid is lysine (K) from the 
AAA codon, followed by the end codon TGA.
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ATGAGTGTGC CCACTCAGGT CCTGGGGTTG CTGCTGCTGT GGCTTACAGA 
TGCCAGATGT GACATCCAGA TGACTCAGTC TCCAGCCTCC CTATCTGTAT 
CTGTGGGAGA AACTGTCACC ATCACATGTC GAGCAAGTGA GAATATTTAC 
AGTAATTTAG CATGGTATCA ACAGAAACAG GGAAAATCTC CTCAGCTCCT 
GGTCTATGCT GCAACAAACT TAGCAGATGG TGTGCCATCA AGGTTCAGTG 
GCAGTGGATC GGGCACACAG TATTCCCTCA AGATCAACAG CCTGCAGTCT 
GAAGATTTTG GGAGTTATTA CTGCCAACAT TTTTGGGGTA CTCCGTACAC 
GTTCGGAGGG GGGACCAGGC TGGAAATAAA ACGTACGGTG GCTGCACCAT 
CTGTCTTCAT CTTCCCGCCA TCTGATGAGC AGTTGAAATC TGGAACTGCC 
TCTGTTGTGT GCCTGCTGAA TAACTTCTAT CCCAGAGAGG CCAAAGTACA 
GTGGAAGGTG GATAACGCCC TCCAATCGGG TAACTCCCAG GAGAGTGTCA 
CAGAGCAGGA CAGCAAGGAC AGCACCTACA GCCTCAGCAG CACCCTGACG 
CTGAGCAAAG CAGACTACGA GAAACACAAA GTCTACGCCT GCGAAGTCAC 
CCATCAGGGC CTGAGCTCGC CCGTCACAAA GAGCTTCAAC AGGGGAGAGT 
GTTAG
Figure 3.2 Nucleotide sequence o f the cB72.3 light chain
The sequence begins with the start codon ATG, as fo r  the heavy chain, but the 
highlighted signal sequence is in this case 60 nucleotides long so that the first 
amino acid is aspartic acid (D) from the codon GAC and the last amino acid is 
cystein (C) from the codon TGT, followed by the stop codon TAG.
QVQLQQSDAE LVKPGASVKI SCKASGYTFT DHAIHWAKQK PEQGLEWIGY 
ISPGNDDIKY NEKFKGKATL TADKSSSTAY MQLNSLTSED SAVYFCKRSY 
YGHWGQGTTL TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP 
VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SW TVPSSSL GTKTYTCNVD 
HKPSNTKVDK RVESKYGPPC PSCPAPEFLG GPSVFLFPPK PKDTLMISRT 
PEVTCVWDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTYRWSVL  
TVLHQDWLNG KEYKCKVSNK G LPSSIEK TI SKAKGQPREP QVYTLPPSQE 
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 
YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K
Figure 3.3 Amino acid sequence o f the heavy chain
The codons have now been transcribed and translated, from the nucleotide 
sequence in Figure 3.1, to the amino acid sequence above. The signal sequence 
has been cleaved o ff so that what can be seen here is the actual heavy chain that 
is used fo r  assembly o f  the IgG; however it is still subject to further modifications 
(see section 3.2).
DIQMTQSPAS LSVSVGETVT ITCRASENIY SNLAWYQQKQ GKSPQLLVYA 
ATNLADGVPS RFSGSGSGTQ YSLKINSLQS EDFGSYYCQH FWGTPYTFGG 
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SWCLLNNFY PREAKVQWKV 
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 
LSSPVTKSFN RGEC
Figure 3.4 Amino acid sequence o f the light chain.
The codons have here been transcribed and translated, from the nucleotide 
sequence in Figure 3.2, to the amino acid sequence and the signal sequence has 
been cleaved off.
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Figure 3.5 Glycosylation structures in IgG
Asn; asparagine 297, GN; N-acetylglucosamine, F; fucose, M; mannose, G; 
galactose. Glycosylation in IgG is o f the complex type with variable glycan 
structures. Most common is the core-fucosylated biantennary structure, as can be 
seen here, built up o f two N-acetylglucosamine residues attached to asn297, 
followed by three mannose residues as the general core structure. Fucose may be 
attached to the first N-acteylglucosamine. Attached to the mannose are two more 
GN residues followed by none, one or two galactose. Sialylation at the galactose 
residues can also occur, but to a lesser extent. Problems with detection and 
quantification o f sialylated versions occur since loss o f sialic acid residues can 
occur.
G lycan M W  (Da)
Fucose (F) 146
Galactose (G) 162
Mannose (M) 162
N-Acetylglucosamine (GN) 203
Sialic acid (Neu5Ac) 291
Table 3.1 Average masses o f the glycan building blocks
Galactose and mannose are both hexoses, while fucose is a hexose deoxy sugar (a 
hydroxyl group has been replaced with a hydrogen) and therefore o f  a lower 
molecular weight. N-acetylglucosamine is an eight carbon derivative o f glucose 
while sialic acid is a derivative o f  the nine carbon monosaccharide neuraminic 
acid.
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In addition to glycosylation, IgG is prone to other modifications. One example is 
the proteolytic degradation of the C-terminal lysine residues (see section 1.6.5). 
Each heavy chain of the IgG has a lysine residue at its C-terminal that can be 
cleaved off, so that theoretically it is possible to end up with a population of mAbs 
with none, one or two C-terminal lysine residues, resulting in a shift in the 
molecular weight of -128 Da per clipped lysine.
Another common modification of IgG is the cyclization of A-terminal glutamine 
to pyroglutamic acid (see section 1.6.5). Each heavy chain has a glutamine (Q) 
residue at its A-terminal, which can be converted into pyroglutamic acid (pE) with 
the loss of an amino group, causing the mass shift of -34 Da (-17 Da per glutamic 
acid). This causes further heterogeneity in the mAh population where again none, 
one or two modifications can take place.
These are some of the main modifications that can be detected when analysing 
intact mAbs on LC/MSD-TOF. Taking them all into consideration, it is obvious a 
large amount of different combinations can occur with a wide range of different 
masses, which are summarised in Table 3.2. What is not known is if all of these 
different structures can be present at the same time, or if some of them are more 
favoured than others. From experience, it seems that some structures are more 
common than other, especially when it comes to glycosylation profiles of mAbs 
(Rehder et al, 2006) where three or four main glycan structures are present rather 
than a more widely heterogeneous population.
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Ab MAN5 GO GOF G1 GIF G2 G2F G2F+sial G2F+2sial
2K, Q 
2K, pE 
IK, Q 
IK, pE  
OK, Q 
OK, pE
143867
143833
143739
143705
143611
143577
146301
146267
146173
146139
146045
146011
146465
146431
146337
146303
146209
146175
146757
146723
146629
146595
146501
146467
146789
146755
146661
146627
146533
146499
147081
147047
146953
146919
146825
146791
147113
147079
146985
146951
146857
146823
147405
147371
147277
147243
147149
147115
147987
147953
147859
147825
147731
147697
148569
148535
148441
148407
148313
148279
Table 3.2 Calculation of theoretical masses of the IgG used in the study
The masses listed in the table result from heterogeneity in the glycosylation pattern together with a few  other commonly occurring modifications. 
The first column indicates what modifications the mAb has been subject to. The native mAb has a lysine residue (K) at the C-terminal o f each 
heavy chain, but these are prone to being cleaved o ff resulting in mAbs with two, one or no terminal lysines (2K, IK  or OK) on the heavy chains, 
corresponding to a mass shift o f -128 Da per lysine residue (see Figure 1.6). The other modification refers to the cyclization o f  the N-terminal 
glutamine (Q) to pyroglutamic acid (pE) which corresponds to a mass shift o f -34 Da (see Figure 1.7), accounting for even more variants as 
shown. The top row shows the nature o f the glycan structure (see Figure 3.5); fo r sake o f demonstration the table shows the masses o f the mAb 
with the two glycan structures being the same on both heavy chain, so the top row should read (G0F)2 etc. From this point forward, the 
structures o f the mAbs will be referred to in coherence with the headings o f this table, e.g. (G0)2-0K-Q, (GlF)2-lK-pE. When the glycan 
structures on the heavy chains o f the same mAb are different, e.g. one is GOF and the other is GIF, the structure will be referred to as 
GOF/GlF-OK-pE etc.
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3.3 HL complexes
The IgG molecule is built up by two heavy and two light chains linked together by 
disulphide bonds. The heavy and light chains are synthesized separately and then 
assembled into the covalently linked IgG tetramer structure H2L2 of a mass of 
approximately 146,000 Da. The IgG subclasses differ in their structure of the 
hinge region, which has an effect on their ability to create these disulphide bonds 
between the two heavy chains. The structure at the hinge region of the IgG4 
subclass causes a non-covalently linked H2L2 tetramer to be co-secreted with the 
covalently linked tetramer (see section 1.6.4). The tetramers lacking the 
disulphide bonds between the heavy chains can disassociate into HL dimers, 
resulting in complexes at half the mass of the intact mAb, i.e. approximately
73,000 Da.
The mAb used in this research is an IgG4, serving as a model antibody, and will 
therefore be subject to the presence of HL dimers as will become evident when 
looking at the results.
3.4 Analysis o f mass spectra
Mass spectrometric analysis of intact mAbs creates complex data that needs to be 
processed and interpreted. This was carried out with the help of Agilent’s 
BioConfirm software (version A.02.00). The data can be viewed in different 
forms. Firstly a total ion chromatogram (TIC) is produced (Figure 3.6) from the 
online desalting where the mAb is captured by the chromatography column 
through hydrophobic interactions and then released to be introduced into the 
ionisation source. This records all the ions present in one signal and is therefore 
not very informative, but can be a useful tool to confirm that the run is working 
properly.
Secondly a mass spectrum is created for the compound (Figure 3.7). This is a plot 
of intensity against the mass-to-charge ratio (m/z) where all the ions are recorded. 
Deconvolution is then carried out with the help of the software in order to create a
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plot of intensity against molecular weight (Daltons). The initial spectrum contains 
a distribution of multiply charged ions. The deconvolution algorithm uses the data 
to calculate the charge states of the ions and the molecular weight of the analyte. 
The plot of the deconvoluted spectrum can be viewed as a whole profile (Figure 
3.8) where all species in the sample can be seen. However, to get more detailed 
information regarding the molecular weight the plot can be zoomed in to focus on 
one area in particular, for example the intact mAb (Figure 3.9). This provides the 
molecular weights of all the different variants in this group showing the 
heterogeneity of the sample, especially regarding the various glycoforms.
Once the mass spectrum has been created showing the molecular weights of the 
variants, the data needs to be interpreted. As can be seen from Figure 3.9 the data 
is rather complex, although some main trends can be observed. The peaks 
represent different glycoforms, but also different modifications such as C-terminal 
lysine cleavage and N-terminal glutamine cyclization. The different peaks need to 
be matched up with the mass variations displayed in Table 3.2. To illustrate the 
evaluation process when assigning the peaks in the spectra to different structures, 
the spectrum in Figure 3.9 has been used as an example and the peaks have been 
numbered as can be seen in Figure 3.10, for easier referral.
A first attempt to assign structures to the different peaks was made by looking at 
the masses of the peaks and then simply trying to find masses in Table 3.2 that 
matched up to the measured ones, as detailed in Table 3.3. This way of 
interpretation leaves a few peaks unidentified as well as several peaks with a large 
mass error. The data from this type of mass spectrometry on such a large molecule 
is not exact, but more likely to have an error of up to about ±5 Da (from 
experience in these studies), which has to be kept in mind when interpreting the 
results. The peaks that are possible to assign also appear to be a bit random, with a 
mixture of the number of C-terminal lysine and N-terminal glutamine residues. It 
seems this assignation method falters in several ways. Instead the mass spectrum 
was viewed as a whole and patterns became obvious. The main peaks are all 
approximately 162 Da apart, which corresponds to the mass of a galactose or a 
mannose. Looking closer at the other peaks, they are all showing patterns with set 
distances from the main peaks and this was used as a basis for the spectral
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interpretation. Figure 3.11, Figure 3.12, Figure 3.13 and Figure 3.14 show the 
thought process where one set of peaks has been identified in each one of the 
figures for clarity. First the main peaks were identified in Figure 3.11, where the 
peaks correspond to the same basic mAb structure with both C-terminal lysine 
residues cleaved off (OK) and both N-terminal glutamine residues converted to 
pyroglutamic acid (pE). The peaks are approximately 162 Da apart, corresponding 
to a galactose residue, resulting in the different glycan structures as detailed in 
Table 3.4, with the exception of peak number one, which is 147 Da smaller than 
the following peak, corresponding to the absence of the core-associated fucose. 
The mass difference of 162 Da also corresponds to the mass of a mannose; 
however the mass patterns do not fit with a high-mannose structure and is 
therefore ruled out. The second set of peaks, identified in Figure 3.12, also differ 
by 162 Da, corresponding to the different glycan structures listed in Table 3.5. 
The peaks in this set also form a pattern with the main peaks in Figure 3.11; each 
one with a mass of +34 Da compared to the associated peak. This corresponds to 
the difference between two pyroglutamic acid residues and two glutamine 
residues, which indicates that the basic mAb structure of the second set of peaks 
has both C-terminal lysine residues cleaved off (OK) but the N-terminal glutamine 
residues (Q) have not been converted. The third set of peaks, identified in Figure 
3.13, again differ by 162 Da, corresponding to the glycan structures described in 
Table 3.6. The peaks again form a pattern with the main peaks in Figure 3.11, but 
in this case they are shifted by +128 Da. This corresponds to the mass of a lysine 
residue, meaning the basic mAb structure of the third set of peaks have both N- 
terminal glutamine residues converted (pE), as with the first set, but still have one 
of the two C-terminal lysine residues intact (IK). The fourth and last set of peaks, 
identified in Figure 3.14, are also 162 Da apart, corresponding to the glycan 
structures in Table 3.7. The peaks in this set are shifted from the main peaks by 
+256 Da. This corresponds to the mass of two lysine residues, so the basic mAb 
structure in this case is determined to have the N-terminal glutamine residues 
converted (pE), but still have both C-terminal lysines intact (2K).
The one peak that has not been identified here using this method is peak number 
two. It could be expected that this peak would be linked to peak number one in the 
same way as the third set of peaks were associated with the other main peaks, i.e.
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with a mass difference of +128 Da. However this is not the case, the difference is 
+94 Da, and by the assignation method used here the identity of this peak still 
remains unclear. Going back to the glycan structures observed by Bailey et al. 
(2005; see Figure 1.11), this could give an explanation to the mass of this peak, 
with a few different possible combinations, however this would open up countless 
possible structures and since these structures have not been commonly observed, 
the peak assignation method from Figure 3.11-3.14 has been adhered to. This 
means there are several possible explanations to the appearance of peak number 
two, but with the method used here it was left unidentified. This has not been a 
major concern in the work presented here, since the spectra have mainly been 
compared in order to spot possible differences and trends. In addition, the peaks 
of most importance are the main peaks identified in Figure 3.11, since they are the 
most prominent and therefore the main contributors to the efficacy of the mAb.
The ESI-TOF analysis has proved to be a very useful tool in the analysis of intact 
mAb. Despite the size of the protein the instrument can detect the masses of the 
sample with great accuracy. Looking at the discrepancies in the sample spectrum 
in Figure 3.10 the average error, when comparing the measured mass with the 
theoretical mass, is less than 30 ppm.
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Figure 3.6 Sample total ion chromatogram of an intact mAb
The TIC records all ions present in the sample in one combined signal. It 
measures the signal intensity over time and corresponds to the liquid 
chromatogram with a slight shift in time since it will be slightly delayed in 
comparison. The data is not selective and does not give any detailed information 
other than confirming the presence o f  an analyte in the sample.
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Figure 3.7 Mass spectrum; sample raw data before deconvolution
The distribution o f multiply charged ions is plotted as intensity against mass-to- 
charge ratio. The ions that can be seen at 1222 and 2422 Da are from the 
calibration solution used to achieve accurate mass. From the charge envelope the 
deconvolution algorithm calculates the charge states o f  the ions and from this 
determines the molecular weight o f  the compound.
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Figure 3.8 Deconvoluted mass spectrum of the whole mass range
After deconvolution the spectrum is plotted as intensity against mass in Da. Here 
it can he seen that there are two main groups o f compounds in the sample — one 
around 73,402 Da and one around 146636 Da. The latter one represents the 
intact mAb while the first one corresponds to half mAbs, i.e. one light and one 
heavy chain. The peak at mass 71,995 Da is non-glycosylated half-antibodies. 
Some minor peaks can also be seen; one at around 48,900 Da, representing the 
heavy chain on its own and also one at around 98,000 Da, which is a complex o f  
two heavy chains.
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146633.8549
146794.9766
Max. 4.4e4 cps.
4.4e4
4.2e4
4.0e4-
3.8e4
3.6e4
3.4e4
3.2e4-
3.0e4
2.8e4
CO 2.6e4-
c
J 2.4e4
O
&
2.2e4
c
0)
2.0e4
_c 1.8e4
1.6e4
1.4e4
1.2e4
1.0e4
8000.0
6000.0
4000.0
2 0 0 0 . 0
0 . 0  J
1.460e5
146473.0218i
146954.5369
146664.6634. 146755.2799 U682 ^  ,0000
j 146589.0148 / 'i A i  
146508.15081—1 f \ '  W  14689^9240 ^147085.8803
146604.3351/ 1/
I \ I ‘ 14705^4821
146551.3693 ^  _  , H 47252 8137
146327.8410 ! 147227.5468-^,
A  / -  146439.6000 
148i05>8073
147376.0940
-147535.7179
1,465e5 1.470e5 
Mass, Da
1.475e5 1.480e5
Figure 3.9 Deconvoluied mass spectrum of the intact mAb.
This represents the group at 146,636 Da from Figure 3.8. The deconvolution was 
this time focused on the area around 146,636 Da to create more detailed data. 
The plot still shows intensity against mass in Dalton. Here the heterogeneity o f  the 
sample can be seen with variants o f the intact mAb shown. The different 
modifications and glycoforms show up as different peaks in the spectrum.
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>- 20,000-
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Figure 3.10 Mass spectrum with assigned peaks
Each peak detected by the MS software has been numbered and listed in Table 3.3 
together with the interpretations o f  their structure. The peaks towards the upper 
end o f the spectrum have been ignored on the basis o f being too small and 
indistinct.
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Peak
no.
Measured 
mass (Da)
Possible structures 
(discrepancy in Da in brackets)
1 146326 G0-1K-Q (+11)
2 146420 G0-2K-pE (+11)
3 146473 G0-2K-Q (-8) or GOF-OK-pE (-6)
4 146505 As above + 0 2 (±0) or G0F-0K-Q (-4) or Gl-OK-pE (-6)
5 146592 GOF-lK-pE (+3)
6 146634 G0F-1K-Q (-5) or G l-lK -pE (-7)
7 146674 As above + 0 2 (-8) or + 2xH20  (-4) or + 2xNa (+6)
8 146755 G0F-2K-Q (+2) or Gl-2K-pE (±0)
9 146795 G1-2K-Q (-6) or GIF-OK-pE (-4)
10 146828
As above + 0 2 (-1) or + 2xH20  (+3) or 
G1F-0K-Q (+3) or G2-0K-pE (-5)
11 146890 ?
12 146921 GIF-lK-pE (-2)
13 146955 G1F-1K-Q (-2) or G2-lK-pE (-4)
14 146992 As above + 0 2 (-5) or 2xH20 (-1) or G2-1K-Q (-7)
15 147046 GlF-2K-pE (+1)
16 147085 G1F-2K-Q (-4) or G2-2K-pE (-6)
17 147114 G2-2K-Q (-1) or G2F-0K-pE (+1)
18 147211 ?
19 147250 G2F-lK-pE (-7)
Table 3.3 Interpretation o f the mass spectrum in Figure 3.10
The peaks detected by the software are listed in the table above detailing their 
assigned peak number, their masses in Dalton and the possible theoretical 
structures at or near the measured masses. For explanations o f  the structures 
listed see section 3.2. All but two peaks could be correlated to at least one mAb 
structure. The unidentified peaks (11 and 18) are barely visible and may not be o f 
great importance, but could indicate that there are other modifications present 
that have not been possible to determine in this study. Most peaks in the table 
above have more than one possible structure correlated to its mass. It is o f course
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possible that multiple structures make up one peak, but in this case it becomes a 
matter ofjudgement o f  what is most likely, drawing from earlier experience in the 
field. First o f all, fo r this particular mAb, the N-terminal glutamine residue will 
have been converted to a pyroglutamic acid, so that the structures including the Q 
residues can be scrapped, cutting the possibilities essentially by half This leaves 
peaks 2, 3, 5, 6 , 8 , 9, 12, 13, 15, 16, 17 and 19 with only one possible structure 
assigned. The first is now without assignation. The second peak has one possible 
structure, but the calculated mass o f this structure is 11 Da bigger than the 
measured value, causing doubt as to whether this is actually the correct structure. 
Peak number four still has two possibilities. Judging the spectrum, it looks more 
likely to be an adduct being so closely linked to the previous peak. Peak seven is 
an adduct o f the previous peak, but from the spectrum it is not possible to 
determine what kind o f adduct. Peak ten has two possible structures, but again it 
looks more likely to be an adduct. Peak fourteen is an adduct, but could be either 
oxygen or water.
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Figure 3.11 Interpretation of mass spectra, main peaks
The most prominent peaks were used as the basis when determining the structures 
behind the masses o f the spectral peaks. A distinct pattern can be seen between 
peak 3, 6 , 9, 13 and 17; they are all around 162 Da (159 Da to 161 Da) apart, 
with a maximum error o f  -3 Da. A mass o f 162 Da corresponds to a hexose. 
Looking firstly at peak number three, it has a measured mass o f 146,473 Da. 
From Table 3.2, this is close to the theoretical mass o f either (G0) 2-2 K-Q 
(146,465 Da) or (G0 F)2-0 K-pE (146,467 Da). Since it is more common that the 
glutamine is converted to pyroglutamic acid than not and the likelihood o f having 
2 intact lysines is small, this peak is determined to be (G0 F)2-0 K-pE. The 162 Da 
addition to this structure corresponds to one galactose, resulting in the structure 
GOF/GlF-OK-pE. The structure with a second addition o f  162 Da then represents 
(GlF)2-0 K-pE or G0F/G2F-0K-pE, the third GlF/G2F-0K-pE and the fourth 
(G2 F)2-0 K-pE, as detailed in Table 3.4. Peak number one is included in the 
pattern, but with a mass 147 Da lower than that o f peak number three. This 
instead corresponds to the absence o f the core-associated fucose (146 Da) and 
represents the structure GO/GOF-OK-pE. All mAbs behind the peaks mentioned 
above include the same modifications; they have both C-terminal lysine residues 
cleaved o ff (OK) and both N-terminal glutamine residues converted to 
pyroglutamic acid (pE).
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Peak no.
Measured
mass
(Da)
Glycan
Theoretical mass 
(Da)
1 146,326 GO/GOF 146,321
3 146,473 (G0F)2 146,467
6 146,634 G0F/G1F 146,629
9 146,795 (G1F)2 or G0F/G2F 146,791
13 146,955 G1F/G2F 146,953
17 147,114 (G2F)2 147,115
Table 3.4 Peak assignation from Figure 3.11
The table lists the first set ofpeaks with their measured mass in Dalton. All peaks 
in this set have the same modifications; they have both C-terminal lysine residues 
cleaved o ff (OK) and both N-terminal glutamine residues converted to 
pyroglutamic acid (pE). Their respective glycan structures are listed in the table 
as well as their theoretical calculated masses in Dalton. With these peak 
assignations the measured masses are correct with errors from -1 Da to + 6  Da.
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Figure 3.12 Interpretation of mass spectra, glutamine not converted
A second set o f peaks can be detected that are also around 162 Da (154 Da to 169 
Da) apart. The reason fo r  the greater variability in masses is that these peaks (4, 
7, 10 and 14) are closely associated with the main peaks and are therefore not as 
prominent. They differ from the main peaks they are associated with by +36 Da 
±4 Da, the connection indicated by dotted lines. The mass difference corresponds 
to the difference between two pyroglutamic acid residues and two glutamine 
residues (+34 Da). The basic structure o f the mAb behind this set o f peaks can 
therefore be determined to have the two C-terminal lysine residues cleaved o ff as 
before (OK), but do not have the N-terminal glutamine converted (Q). The glycan 
structures corresponding to the peaks are (G0 F) 2  (peak number 4), G0F/G1F (7), 
(GIF) 2 or G0F/G2F (10) and G1F/G2F (14), as detailed in Table 3.5.
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Peak no.
Measured mass 
(Da)
Glycan
Theoretical mass 
(Da)
4 146,505 (G0F)2 146,501
7 146,674 G0F/G1F 146,663
10 146,828 (G1F)2 or G0F/G2F 146,825
14 146,992 G1F/G2F 146,987
Table 3.5 Peak assignation from Figure 3.12
The table lists the second set o f peaks with their measured mass in Dalton. All 
peaks in this set have the same modifications; they have both C-terminal lysine 
residues cleaved o ff (OK) but differ from the peaks in the first set (Figure 3.11 and 
Table 3.4) by having the N-terminal glutamine residues intact (Q). Their 
respective glycan structures are listed in the table as well as their theoretical 
calculated masses in Dalton. With these peak assignations the measured masses 
are correct with errors from +4 Da to +9 Da. The greater discrepancies in this 
set compared to the first is due to the small mass difference (+34 Da) between 
these peaks and the main peaks and the inability o f the software to correctly make 
a distinction o f this much smaller peak from the main peak it is associated with.
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Figure 3.13 Interpretation o f mass spectra, one intact lysine
A third set o f peaks can be detected that are again around 162 Da (163 Da to 166 
Da) apart. They differ from the main peaks they are associated with by +127.5 Da 
±8.5 Da, the connection indicated by dotted lines. This mass difference 
corresponds to the mass o f  one lysine residue, indicating that the basic structure 
o f the mAb behind this set ofpeaks have the N-terminal glutamine converted (pE) 
as in the first set o f peaks but only have one o f the two C-terminal lysine residues 
cleaved o ff (IK). The glycan structures corresponding to the peaks are (GOF) 2 
(peak number 5), GOF/GIF (8), (G1F) 2 or G0F/G2F (12), G1F/G2F (16) and 
(G2F) 2 (19), as detailed in Table 3.6.
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Peak no.
Measured mass 
(Da)
Glycan
Theoretical mass 
(Da)
5 146,592 (G0F)2 146,595
8 146,755 G0F/G1F 146,757
12 146,921 (G1F)2 or G0F/G2F 146,919
16 147,085 G1F/G2F 147,081
19 147,250 (G2F)2 147,243
Table 3.6 Peak assignation from Figure 3.13
The table lists the third set o f peaks with their measured mass in Dalton. All peaks 
in this set have the same modifications; they have both N-terminal glutamine 
residues converted (pE) but differ from the peaks in the first set (Figure 3.11 and 
Table 3.4) by having one o f the C-terminal lysine residues intact (IK). Their 
respective glycan structures are listed in the table as well as their theoretical 
calculated masses in Dalton. With these peak assignations the measured masses 
are correct with errors from -3 Da to +7 Da.
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Figure 3.14 Interpretation of mass spectra, two intact lysines
A fourth set o f  peaks can be detected that are again around 162 Da (156 Da and 
165 Da) apart. They differ from the main peaks they are associated with by 
+253.5 Da +2.5 Da, the connection indicated by dotted lines. This mass difference 
corresponds to the mass o f two lysine residues, indicating that the basic structure 
o f the mAb behind this set ofpeaks have the N-terminal glutamine converted (pE) 
as in the first set ofpeaks but have both C-terminal lysine residues intact (2K). The 
glycan structures corresponding to the peaks are GOF/GIF (peak number 11), 
(GIF) 2 or G0F/G2F (15) and G1F/G2F (18), as detailed in Table 3.7. This set o f  
peaks could possibly have the addition o f a peak directly to the left o f  peak 
number eight, since that is a wider peak that could hide the integration o f  a 
smaller peak that the software finds difficult distinguishing from the other one.
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Peak no.
Measured mass 
(Da)
Glycan
Theoretical mass 
(Da)
11 146,890 G0F/G1F 146,885
15 147,046 (G1F)2 or G0F/G2F 147,047
18 147,211 G1F/G2F 147,209
Table 3.7 Peak assignation from Figure 3.14
The table lists the fourth set o f peaks with their measured mass in Dalton. All 
peaks in this set have the same modifications; they have both N-terminal 
glutamine residues converted (pE) but differ from the peaks in the first set (Figure 
3.11 and Table 3.4) by having both C-terminal lysine residues intact (2K). Their 
respective glycan structures are listed in the table as well as their theoretical 
calculated masses in Dalton. With these peak assignations the measured masses 
are correct with errors from -1 Da to +5 Da.
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4 Effect of harvest time on the molecular structure 
and conformation of a mAb
This study examines the effect of time of harvest on the molecular structure of the 
recombinant IgG B72.3. The glycosylation status of whole recombinant IgG at 
different stages of fermentation was compared. Two separate fermentations were 
compared where the same cell line, media and culture conditions were used (for 
details see section 2.1).
4.1 Growth profiles
Figure 4.1 shows the growth profile of the first fermentation that was investigated. 
Samples were taken on day 6, 7, 11, 14 and 17 to obtain coverage throughout the 
different stages of fermentation. Figure 4.2 shows the logarithmic growth curve 
providing an overview of the growth phase of the cells during the fermentation. 
Table 4.1 details the conditions for each sampling point, which will be of 
importance when interpreting the data. Figure 4.1 and Table 4.1 show that 
between day 11 and day 14 the fermentation is starting to reach higher mAb titres, 
but at the same time cell viability is also significantly starting to suffer. There is 
an obvious decrease in cell viability between day 14 and day 17 when harvest was 
carried out. It is important to note here that most mammalian cell cultures of this 
kind are normally harvested on day 14 or 15. The reason for keeping the 
fermentation going to day 17 was to look at how the mAb concentration and 
overall performance of the culture change over the last couple of days. From this 
data it can be seen that there is no significant increase in product titres from day 
14 to day 17, while there are significant decreases in cell viability, explaining the 
industry choice of harvesting after 15 days.
In order to confirm the findings from fermentation 1, a second fermentation was 
carried out. This time the culture was only kept until day 15, rather than day 17, 
when harvest was carried out, which is more representative of commercial 
standards for this application. The second fermentation showed a slightly slower 
start, both in terms of growth and product formation, especially the latter, as can 
be seen in Figure 4.3. However, after the first two days the growth and product
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Figure 4.1 Growth profile o f cell culture, 1st fermentation
Symbols represent total number o f cells (m ); number o f viable cells (A ); mAb 
formation (A). Points are single measured values and lines were drawn as best f i t  
by eye. A 10 L fermenter was used with a working volume o f  8.5 L, fe d  batch (see 
section 2.1). The arrows indicate time points when samples were taken (days 6 , 7, 
11, 14 and 17).
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Figure 4.2 Logarithmic growth curve, 1st fermentation
Lag phase was absent in this fermentation and instead exponential phase was 
experienced immediately for the first four days after which the cells entered 
stationary phase, which then lastedfor the remainder o f the fermentation.
Sample Growth phase
Antibody titre 
(g/L)
% cell 
viability
Day 6 Early stationary 0.2 98
Day 7 Early stationary 0.3 97
Day 11 Late stationary 1.2 94
Day 14 Death phase 1.7 90
Day 17 Death phase 1.8 43
Table 4.1 Growth characteristics, 1st fermentation
Six samples were taken and analysed at different stages o f  the fermentation; 
during early stationary (day 6  and 7), late stationary (day 11 and 14) and finally 
at time o f harvest (day 17). Cell viability was high and stayed steady over the first 
two samples, starting to decrease around day 1 1  and from day 14 the cells started 
to die rapidly with significant cell death at time o f harvest and last sampling 
point.
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Figure 4.3 Growth profile o f cell culture, 2nd fermentation
Symbols represent total number o f cells (M); number o f viable cells (A) and mAb 
formation (A). Points are single measured values and lines were drawn as best f i t  
by eye. A 10 L fermenter was used with a working volume o f 8.5 L, fe d  batch (see 
section2.1). The arrows indicate time points when samples were taken (day 8 , 11, 
14 and 15).
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Figure 4.4 Logarithmic growth curve, 2ndfermentation
Lag phase was experienced fo r  the first day or two before the cells went into 
exponential phase from day 2 to 7. From day 10 stationary phase was experienced 
fo r the remainder o f  the fermentation.
Sample Growth phase
Antibody titre 
(g/L)
% cell 
viability
Day 8 Early stationary 0.3 97
Day 11 Stationary 1.0 97
Day 14 Late stationary 2.5 97
Day 15 Late stationary 2.9 96
Table 4.2 Growth characteristics, 2nd fermentation
Four samples were taken and analysed at different stages o f  the fermentation; 
during early stationary (day 8), mid stationary (day 11), late stationary (day 14) 
and finally at time o f harvest (day 15). Cell viability was high and stayed level 
over the main part o f the culture with only small losses in viability towards time o f 
harvest.
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formation rate was very similar to that of the first fermentation. From the log 
growth curve in Figure 4.4 it becomes obvious that this second fermentation had a 
slight lag phase before exponential phase was reached by day two. A consequence 
of this is that the viability stays high for the duration of the fermentation until time 
of harvest. Samples were taken during different growth phases on days 8, 11, 14 
and 17, with conditions for each sampling point with regard to growth phase and 
cell viability detailed in Table 4.2.
4.2 Glycosylation profiles
The samples taken were purified (see sections 2.2 and 2.6), analysed by LC/MSD- 
TOF (for conditions see section 2.9.1) and deconvoluted. The mass spectra were 
then normalised so that the areas of all spectra were identical, in order to compare 
the relative amounts of each peak (Figure 4.5). Due to the noise levels from the 
solvents the spectra are rather complex and the smaller peaks have at this point 
not been investigated closer; instead the focus has been on trends among the main 
peaks. The peaks were assigned as detailed in section 3.4. The identified peaks all 
have the same modifications to the basic mAb structure; both C-terminal lysine 
residues have been cleaved off and the N-terminal glutamine residues have been 
converted to pyroglutamic acid (see section 1.6.5). One mAb can have either two 
of the same glycans attached to each heavy chain, or two different ones. As can be 
seen from the spectra, the glycans vary from GO to G2F (for structures see section 
3.2, Figure 3.3) and the overall trend is that the level of galactosylation decreases 
over time of culture. On day six, the most abundant glycoform is (G1F)2, however 
this shifts with time; on day seven the most abundant glycoform is 162 Da 
smaller, representing the G0F/G1F glycoform. Towards the later stages of culture 
it has shifted even further by another 162 Da and the most abundant glycoform is 
(G0F)2 on days 11, 14 and 17. The whole spectrum shifts towards the left, clearly 
showing that the glycans are becoming less complex over time of fermentation.
The data from the first fermentation gives clear information related to the major 
peaks. In order to better interpret the smaller peaks, the protocol was redesigned 
for the second fermentation (for conditions see section 2.9.1). The drying gas 
temperature was increased to provide a clearer spectrum with less noise as can be
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seen in Figure 4.6. Looking at the main peaks, the trends agree well with the 
observations from the first fermentation; the level of galactosylation decreases 
with time of culture. There is a shift in the main glycoform from G0F/G1F on day 
8 towards (G0F)2, with an obvious decrease in the (G1F)2 glycoform at the same 
time as the (G0F)2 variant is increasing. The lower noise levels in these spectra 
also allow a more detailed analysis, taking all peaks into consideration and not 
only the most intense ones. In these spectra, not only the different glycoforms can 
be detected, but also other modifications to the basic mAb structure (see section 
1.6.5). Small, incompletely resolved peaks are evident at a mass of +34 Da from 
each main peak. This corresponds to the difference in mass between pyroglutamic 
acid and glutamine, indicating that the mAbs behind these second peaks have not 
had the N-terminal glutamines converted. The spectra also show resolved peaks 
corresponding to mAbs with the same glycoforms as the main peaks, but with 
different amounts of intact C-terminal lysines; peaks at +128 Da with one intact 
lysine as well as peaks at +256 Da, with both lysines intact.
4.3 Glycoform production
In order to understand better the reasons behind the changes in glycoform 
production, the total product formed in picograms per cell per day (PCD) was 
calculated and plotted in Figure 4.7. During the first stages of culture while the 
cells are in exponential phase, the product formation per viable cell remains 
approximately constant rather than increasing, which could be due to the cells 
focusing on growth rather than mAb formation. During the later stages of the 
exponential phase, the mAb production per viable cell increases rapidly and stays 
steady during early stationary phase, which is when the cell specific activity is at 
its highest. During this stage, the cells are no longer focusing on growth, but are 
still in a good state and this is where most of the product is being formed. The 
mAb production per viable cell then decreases until time of harvest when it almost 
reaches zero. This could be due to the state of the viable cells during this stage 
and the counting method used (the Vi-Cell is based on the trypan blue method). 
Even if the cells are still counted as viable, they will not be in a favourable state 
and will have decreased functionality. Apoptotic cells will have shut down certain 
protein production mechanism for example.
101
Cecilia Reid Chapter 4
4,000
G1F)3^1F' G2F)2u£r
4,000
M— GN
GOM— GN
M— GN 
M— GN
Asn— GN— G N - N ff GOF
4,000 M— GN 
M— GN—
G IF
M— GN— G 
M— GN— G G2F
4,000
147:000146,000 148,000
Mass (Da)
Figure 4.5 Effect of harvest time on the glycosylation pattern o f an IgG, 1st 
fermentation.
Legend on following page.
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Figure 4.5 continued. The figure shows the mass spectra from day 6  (a), 7 (h), 11 
(c), 14 (d) and 17 (e) o f  culture. LC/MSD-TOF was used to analyse the intact 
antibody, resulting in the above spectra. Looking at the most prominent peaks, 
these create a pattern, separated by approximately 162 Da, corresponding to the 
mass o f a galactose, with the exception o f the first and second main peaks that 
instead are separated by 146 Da; the mass o f a fucose. The figure indicates the 
basic glycoforms GO, GOF, GIF and G2F (see Figure 3.5) and how they are 
represented in pairs on the intact mAb (one on each o f the two heavy chains). The 
mAbs are also prone to other modifications, such as C-terminal lysine cleavage 
and cyclization o f the N-terminal glutamine residue (see section 1.6.5). All o f the 
main peaks have the same modifications in this respect; both lysines have been 
cleaved o ff (OK) and the glutamine has been converted to pyroglutamic acid (pE) 
(for more details see Table 3.2). The other peaks that can be seen in the spectra 
are variations o f these modifications, causing the heterogeneity in the mAb 
population. There is also a certain level o f noise from the solvents involved in the 
analysis, which is the reason the smaller peaks have not been given more 
attention. The most prominent peaks are obviously the main contributors to the 
mAb population, so these have been analysed in more detail. Looking at the two 
extremes as shown in a) the profile from day six and e) the profile from day 
seventeen, a shift in masses can be seen over the course o f  culture. In a) the 
lowest masses start at 146,400 Da, while in e) the whole mass spectrum has 
shifted towards the left with masses starting at 146,200 Da. The main peak has 
shifted by 324 (2x162) Da from 146,795 Da on day 6 , corresponding to the GIF  
glycan attached to both heavy chains, to 146,471 Da on days 11, 14 and 17, 
corresponding to the GOF glycan attached to both heavy chains. The shift in the 
spectra indicates that the sugars are becoming less complex towards the end o f  
fermentation.
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Figure 4.6 Effect of harvest time on the glycosylation pattern of an IgG, 2nd 
fermentation
The figure shows the mass spectra from day 8  (a), 11 (b), 14 (c) and 15 (d) o f  
culture. As in Figure 4.5, the basic glycoforms are indicated; GO, GOF, GIF and 
G2F and how they are represented in pairs on the intact mAb and again all o f  the 
main peaks have the same modifications to the basic structure; both lysines have 
been cleaved o ff (OK) and the glutamine has been converted to pyroglutamic acid 
(pE). The observations made fo r  the first fermentation are well supported by this 
secondfermentation. There is an increase in the lower masses over time o f  culture 
at the same time as there is a decrease in the higher masses. The main glycans 
shift with time from GOF'/GIF on day 8  towards (GOF)2, the level o f  
galactosylation decreasing with time. The lower noise levels in these optimised 
spectra also make it possible to start looking closer at the less intense peaks. All 
o f the main peaks have a “heel ” on them, indicating there is a second peak there 
that has not been completely resolved due to the similarity in mass o f  the two 
peaks. This second peak has a mass o f +34 Da compared to the main peak it is 
connected to. This corresponds to the difference in mass between pyroglutamic 
acid and glutamine, indicating that these second peaks have the same glycans 
attached as the main peaks, but the N-terminal glutamines have not been 
converted. There is also another peak at +128 Da from each main peak. This
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corresponds to a mAb carrying the same glycans but still has one C-terminal 
lysine intact. I f  looking closely, an additional peak can be detected, at +256 Da 
from each main peak, which in turn corresponds to the same mAb structure but 
with both C-terminal lysines intact. For a more detailed explanation o f  
interpretations see section 3.4.
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The total amount of mAb produced per cell per day was then used to investigate 
the production rate of the different glycoforms. The areas of the peaks in the 
spectra from Figure 4.5 were measured and the amount of each glycoform 
produced per viable cell per day was calculated and plotted in Figure 4.8. With the 
exception of the GO/GOF glycoform, all lines seem to follow the development of 
the total product formed, just with different magnitudes, which is the trend that 
might have been expected. The increase in GO/GOF formation is concurrent with a 
decrease in cell viability and could be related to increased stress levels.
As for the first fermentation, the total product formed per viable cell per day was 
calculated and plotted in Figure 4.9. The trend of this curve is very similar to what 
was observed for the first fermentation, only with a slightly later response due to 
the lag phase experienced at the beginning of the culture. Again the production 
rate is staying rather level for the early stages, during exponential growth phase to 
then increase sharply towards the end of the growth phase and reaching the 
highest values during early stationary phase when a large amount of the product is 
being formed. In contrast to the first fermentation, total product formed per viable 
cell per day in this second fermentation does not reach zero towards time of 
harvest. This can be explained by the lag phase experienced as well as the earlier 
harvest time.
The amount of each glycoform produced per viable cell per day was then 
calculated using the areas of the peaks of the spectra in Figure 4.6 and plotted in 
Figure 4.10. As for the first fermentation, the (G0F)2 and the G0F/G1F 
glycoforms seem to follow the development of total mAb formed per viable cell 
per day. In contrast to before, the GO/GOF glycoform now also follows the trend 
of the total product formed and can therefore be grouped together with the two 
first mentioned. The formation of (G1F)2, G1F/G2F and (G2F)2 in this case seems 
to increase with time for reasons not fully understood. A possible explanation is 
that due to the lag phase and delay in product formation the production rates for 
these glycoforms have not yet dropped off, but if harvest had been carried out a 
few days later the decrease would have been visible.
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Figure 4.7 Product formation, 1st fermentation
Shown here is the product formation over time o f culture (+) (in grams) and 
product formation ( o  ) in picograms per viable cell per day (PCD). The total 
amount o f mAb produced per cell per day was calculated as an average between 
two measured points and plotted with the axis on the left. Up until day six the 
product formation per viable cell is staying fairly steady rather than increase. 
After day six, as the culture is reaching the later stages o f  the exponential phase, 
the mAb production per viable cell increases sharply until day nine when the cells 
reach stationary phase. It then decreases rapidly until time o f harvest when 
product per viable cell per day almost reaches zero.
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Figure 4.8 Formation o f different glycoforms per viable cell per day, 1st 
fermentation
The total amount o f mAb produced per cell per day was plotted with the axis on 
the right. To generate the lines representing the amount o f each glycoform formed  
per viable cell per day the areas o f the peaks o f the mass spectra from Figure 4.5 
were calculated, and the relative amounts o f the glycans representing the main 
peaks were calculated. This value was then multiplied with the total amount o f  
mAb produced per cell per day. The symbols represent the following: (+) Total 
product, (+) G0/G0F, (M) (G0F)2, (A) G0F/G1F, (x) (G1F)2, (2 ) G1F/G2F, ( • )  
(G2F)2. Looking at the trends o f the lines, G0/G0F (A) is the only glycoform that 
increases with time. The (G0F) 2 ( * ) ,  G0F/G1F (A) and (G1F) 2 (x) glycoforms 
more or less follow the development o f the total product being formed, which is 
the trend that might have been expected. The last and most complex glycoforms, 
G1F/G2F (O ) and (G2F) 2 ( 9 ) ,  seem to stay almost constant at a first glance. 
However, when expanding the axis fo r  these two lines they both follow the trend 
o f the total product formed and the other glycoforms, except G0/G0F, only with 
smaller variations.
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Figure 4.9 Product formation, 2nd fermentation
Shown here is the product formation over time o f culture (+) (in grams) and 
product formation in picograms per viable cell per day p). Product formation per  
viable cell per day increases fo r  the duration o f the exponential growth phase and 
during early stationary phase, up until day 12. From this point onwards, the 
viable cells produce decreasing amounts o f product per day, while the cells are in 
stationary phase.
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Figure 4.10 Formation of different glycoforms per viable cell per day, 2nd 
fermentation
The lines representing the amount o f glycan formed per viable cell per day were 
generated as detailed in the legend fo r  Figure 4.8 but using the mass spectra in 
Figure 4.6 rather than Figure 4.5. The symbols represent the following: (+) Total 
product, (+) GO/GOF, (m) (G0F)2, (A) G0F/G1F, (x) (G1F)2, (D)  G1F/G2F, (9)  
(G2F)2. The trends o f the lines can divide the glycoforms into two groups. In this 
case, the GO/GOF (9 ) glycoform, upon expansion o f the axis, follows the trend o f  
the total product formed per viable cell per day and can therefore be grouped 
together with (G0F) 2 (M ) and GOF/GIF (A ), The formation o f  (G1F) 2 (x) per 
viable cell in this case seems to increase with time as do G1F/G2F (D  ) and 
(G2F)2 (9).
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4.4 Half antibodies
So far, the focus has been on the molecular structure of the intact mAb and its 
glycosylation pattern. If instead looking at the overall composition of the product, 
the intact mAb is not the only evident structure that has been purified by protein A 
chromatography, as detailed in Figure 4.11. This shows everything that was 
detected in a wider mass range; from 10,000 Da up to 155,000 Da. The noise 
levels in these spectra make the data rather messy and difficult to interpret, 
however, it still becomes obvious that in addition to the intact mAb at 
approximately 147,000 Da, there is another structure present, giving rise to peaks 
at 73,000 Da, approximately half the mass of the intact mAb. This structure is the 
HL dimer, or so called half-antibody (see section 1.6.4) that is the result of the 
non-covalently bound H2L2 tetramer, which in this case has fallen apart into two 
HL dimers. Looking more closely at these structures it becomes clear that the 
tetramers that are non-covalently bound have the same glycosylation pattern as 
the covalently bound tetramers, with the main glycoform shifting from GIF on 
days six and seven, to GOF on days 11, 14 and 17. This justifies only taking the 
intact mAb into account when doing the glycan analysis detailed above.
Figure 4.12 shows the mass spectra of the samples from the second fermentation 
with the wider mass range from 10,000 Da to 155,000 Da, where the intact mAb 
as well as the non-glycosylated and glycosylated half-antibody is visible. Due to 
the lower noise levels in these spectra it becomes possible to do a more detailed 
interpretation of the data. By visual inspection it looks like the proportion of half­
antibodies is decreasing over time of culture; the non-glycosylated half-Abs seem 
to only slightly decrease, while the glycosylated dimers seem to decrease more 
notably. As for the first fermentation, the mass of the glycosylated half-Ab shifts 
from having the GIF glycoform on day 8 towards having the GOF glycoform on 
days 11, 14 and 15, supporting the observations from Figure 4.6.
Due to the different ionisation potentials of the HL dimer and the H2L2 tetramer 
the amounts are not quantifiable, but the general trend can be studied by looking 
at the relative amounts; the peak of highest intensity was set to 1 and the ratios of 
the intensities of the other peaks to the highest were calculated as detailed in
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Figure 4.11 Effect of harvest time on the overall mAb composition, 1st 
fermentation.
Legend on following page.
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Figure 4.11 continued. The traces correspond to the samples in Figure 4.5, but 
here the whole mass range is shown as an overview; from 10,000 Da to 180,000 
Da. The spectra contain a lot o f noise due to solvents, so no detailed information 
can be obtained from this figure. However, it still becomes obvious that there are 
two main peak clusters; one with masses around 73,000 Da and one with masses 
around 146,000 Da. The higher mass peak cluster, at 146,000 Da, corresponds to 
the intact antibody, while the lower mass peak cluster corresponds to a “half­
antibody” made up o f one heavy and one light chain (see section 1.6.4). Looking 
closer, there are two distinct peaks here; the one o f the lower mass, less than
72,000 Da, corresponds to a non-glycosylated HL dimer, while the one with a 
slightly higher mass, over 73,000 Da, corresponds to a glycosylated HL dimer. 
The mass o f  the latter peak shifts from 73,396/7 Da in a) and b) (day 6  and 7) to 
73,234/7 in c), d) and e) (day 11, 14 and 17). The mass during day 6  and 7 
corresponds to a HL dimer with the C-terminal lysine on the heavy chain cleaved 
off and the N-terminal glutamine on the heavy chain converted to pyroglutamic 
acid, plus the GIF glycan attached at Asn297. On day 11, the mass o f  the peak 
shifts to correspond to a HL dimer with the same basic structure, but instead o f  
the GIF glycan, it has the GOF glycan attached. This data correlates nicely with 
the findings from figure 4.3; the complexity o f the glycans decreases over time o f  
culture and also shows that the glycosylation patterns are the same fo r  the non- 
covalently bound H2L2 tetramers, that here have dissociated into dimers, as for  
the covalently bound tetramer.
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Figure 4.12 Effect of harvest time on the overall mAb composition, 2nd 
fermentation
The traces correspond to the samples in Figure 4.6, but here the whole mass 
range is shown as an overview; from 10,000 Da to 180,000 Da. The peak o f  
highest intensity was set to 1  and from this the relative amount o f each structure 
could be determined. Three main distinct peaks can be seen that are actually 
clusters o f  peaks when looking more closely, corresponding to the different 
modifications and glycosylation patterns present. There is one group just under
72,000 Da, which corresponds to non-glycosylated HL dimers, i.e. “half-Abs” 
(see section 1.6.4). The second one is the glycosylated form o f the HL dimer, with 
masses on 73,000 Da. The third peak is the intact Ab, with the main peak at 
146,636 Da, corresponding to the basic antibody structure with both C-terminal 
lysines cleaved off (OK), the N-terminal glutamines converted to pyroglutamic 
acid (pE) and with the G0F/G1F glycoform. From determination by eye, it seems 
the proportion o f HL dimers is decreasing over time o f culture, from day 8  to day 
15. The non-glycosylated half-Abs seem to only slightly decrease, while the 
glycosylated half-mAbs seem to decrease more notably. The mass o f the latter 
shifts from 73,396 Da on day 8  towards 73,234 Da on days 11, 14 and 15. A mass
95J00Q1CJ000
Mass (Da)
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o f 73,396 Da corresponds to the HL dimer with both lysines cleaved off (OK), the 
glutamine converted to pyroglutamic acid (pE) and with the GIF glycoform 
attached to the heavy chain, while a mass o f 73,234 Da corresponds to the same 
basic mAb structure, but with the GOF glycoform attached. These findings 
correlate nicely with the observations from Figure 4.6; the level o f 
galactosylation decreases with time o f culture. From this it can also be concluded 
that the non-covalently bound H2L2 tetramers carry the same glycoforms as the 
covalently bound tetramers.
Day
Half-mAb
(non-glyc)
Half-mAb Intact mAb
8 0.28 : 1 0.9
11 0.22 0.57 : 1
14 0.16 0.31 : 1
15 0.17 0.32 : 1
Table 4.3 Effect of harvest time on the proportion of HL dimers, 2nd 
fermentation
From Figure 4.12 the relative amounts o f non-glycosylated half-mAb, 
glycosylated half-mAb and intact mAb were measured and the ratios o f  the three 
were calculated as can be seen in the table above. The first figure represents the 
non-glycosylated HL dimers, the second represents the glycosylated HL dimers 
and the last is the intact mAb. These calculations confirm the initial observations 
from Figure 4.12; the relative amounts o f both non-glycosylated and glycosylated 
half-Abs decrease with time, by 40% and 70% respectively.
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Table 4.3. The calculated values support the observations made by eye from 
Figure 4.12; the proportion of half-Abs decreases with time, the non-glycosylated 
dimer by 40% and the glycosylated dimer by 70%.
4.5 Lysine and glycoform levels
The lower noise levels of the mass spectra in the second fermentation allow for a 
comparison of lysine levels on the mAb in samples from different times in culture, 
represented by a histogram in Figure 4.13. This shows that the predominant 
structure has both lysine residues cleaved off (OK) at a level of 60-67% of the 
mAb population while structures with one or two intact lysines make up 20-25% 
and 12-16% respectively. This was also confirmed by analysis of a deglycosylated 
mAb (Figure 4.14), which shows one main peak representing the intact mAb with 
both N-terminal glutamine residues converted to pyroglutamic acid and both 
lysines cleaved off. It also shows a second peak where the mAb still has one intact 
lysine, representing approximately 17% of the population and a third peak where 
both lysines are still intact, representing approximately 5%. Since the lysine levels 
stay more or less constant over the time course of culture, regardless of glycan 
structure, it was thought justified the decision to concentrate on the main peaks 
(both lysine residues cleaved) for the glycan analysis. A more detailed analysis of 
the amounts of the different glycoforms was also carried out. The relative amount 
of each glycoforms was calculated from the spectra in Figure 4.6, taking into 
account all lysine variants (OK, IK and 2K) and then plotted as a histogram in 
Figure 4.15. This gives an overview of how the proportions of the glycoforms 
change over time of culture and aids in showing how the glycoforms with a lower 
degree of galactosylation, GO/GOF and (G0F)2, increases in proportion over time, 
while the more complex glycans, (G1F)2, G1F/G2F and (G2F)2 decreases. This 
agrees nicely with the initial observations made by visual inspection of Figure 4.6.
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Figure 4.13 Lysine levels over time, 2nd fermentation
The relative intensities o f the peaks representing different numbers o f  lysines were 
compared. All mAb versions (i.e. different glycan forms) o f OK fH ), IK  (HO ) and 
2K (M ) were added together and the relative amount was calculated fo r  each o f 
them and plotted as a histogram, above. The predominant structure (60-67%) has 
had both lysine residues cleaved off, OK, with structures o f one and two intact 
lysines representing 20-25% and 12-16%> respectively. The above representation 
shows that the lysine levels stay fairly constant over time o f culture, possibly with 
a slight increase in the OK variant towards the end o f fermentation.
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Figure 4.14 Deglycosylated mAb
Deglycosylation o f the mAb was carried out (for conditions see section 2.7.1) and 
the mAb was then analysed again using LC/MSD-TOF resulting in the spectrum 
above. The main peak at 143,583 Da represents the intact deglycosylated mAb 
with both lysines cleaved o ff and both glutamine residues converted to 
pyroglutamic acid (theoretical mass 143,577 Da). The second prominent peak has 
a mass increase o f 126 Da as compared to the main peak, representing the intact 
deglycosylated mAb with one lysine intact (theoretical mass 143, 705 Da). A third 
peak is also visible at +253 Da compared to the main peak, representing the 
intact deglycosylated mAb with both lysines still intact (theoretical mass 143,833 
Da).
118
Cecilia Reid Chapter 4
11 14
Day
f c
15
Figure 4.15 Glycoform levels over time, 2nd fermentation
From Figure 4. 6  the area o f each peak was measured and the relative amounts o f  
the glycoforms were calculated, taking into account all lysine variants (OK, IK  
and 2K). The resulting histogram gives an overview o f how the proportions o f  the 
glycoforms change over time o f culture. The bars represent the following 
glycoforms; ( U )  GO/GOF, ( M )  (G0F)2, ( W  GOF/GIF, ( M )  (G1F)2, ( W  
G1F/G2F, (□  )  (G2F)2. The figure shows clearly how the glycoforms with a lower 
degree o f  galactosylation, GO/GOF and (G0F)2, increases in proportion over time, 
while the more complex glycans, (G1F)2, G1F/G2F and (G2F) 2 decreases over 
time. The GOF/GIF mAb contains one glycoform with lower levels o f  
galactosylation and one with higher and shows a nice correspondence by staying 
at a constant proportion over time.
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4.6 Discussion
The two separate fermentations were carried out using the same cell line, media 
and culture conditions. If the slight lag phase that was experienced during the 
second culture is disregarded, the two fermentations were very similar with 
respect to cell growth and they should therefore give good indications to the 
reproducibility of the results on mAb structure and conformation as well as any 
variations between batches. The combined results help us gain a better 
understanding of the events determining structure.
The first fermentation was kept until day 17 in order to look at how the mAb 
concentration and overall performance of the culture change over the last couple 
of days. From this data it can be seen that there is no significant increase in 
product titres from day 14 to 17, while there is a very marked decrease in cell 
viability during the same period. With dying cells there is an increase in cell lysis, 
which would then lead to the release of intracellular material. This could in turn 
make subsequent purification steps harder, making it important to reach a balance 
between mAb production and cell death. The rapid decrease in viability and the 
relatively small increase in product titres over these last two to three days of 
culture explain the reasons behind the industry standard to harvest on day 15.
The main focus of this study was to look at the integrity of the molecular structure 
of the mAb over time of culture. It is of common knowledge that the C-terminal 
lysine residues of mAb produced by mammalian cell culture are prone to 
cleavage. MAb populations with almost complete absence of C-terminal lysines 
have previously been reported (Beck et al, 2005; Harris et al, 1990). In contrast, 
here it was shown that approximately two thirds of the final product have had both 
lysines removed, 20-25% have one lysine and 12-16% still have both lysines 
intact, similar to observations made by Santora et al. (1999). We have shown that 
the lysine levels of the mAb population stay relatively constant over time of 
culture, possibly with a slight decrease in intact lysine residues. This is however 
not of great importance with respect to the efficacy of the mAb, since the presence
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of a C-terminal lysine residue does not impact the activity. However it could be of 
concern for validation purposes.
What is of greater importance is the glycosylation pattern due to its relationship to 
crucial attributes, such as stability (Broersen et al, 2004; Krapp et al, 2003; 
Mimura et al, 2000) and activity (Lund et al, 1996). The peak distribution of the 
mass spectra shows that two different glycans can be attached to the heavy chains 
of a mAb H2L2 tetramer, which has been reported previously (Gadgil et al, 2006). 
From the mass spectra of both fermentations it becomes evident that the 
glycosylation pattern of the mAb is changing over time of culture. The main 
glycoform shifts from (G1F)2, when the cells are in late exponential/early 
stationary phase, to (G0F)2, towards the end of culture, i.e. a decrease in the level 
of galactosylation is experienced. The GOF glycan is the most abundant at time of 
harvest, which is in accordance with previous findings (Krapp et al, 2003). The 
explanation for the observations of decreased levels of galactosylation over time 
can be one or more of several: the antibodies could be modified while in the broth 
by for example proteolytic degradation; glycosylation could be compromised due 
to production of high antibody titres, i.e. the cells are stressed and therefore failing 
to attach additional galactose residues; the cells could be starting to lyse. The two 
last mentioned explanations would both lead to the release of incompletely 
processed material, such as glycoforms with lower levels of galactosylation. It is 
at this point difficult to determine which one or what combination of the factors 
are the underlying reason for the observations made, but subsequent experiments 
(discussed in chapter 6) have been designed to rule out some hypotheses.
Glycosylation is affected by various changes in the operating environment; 
previous studies have reported changes in glycosylation patterns with different 
culture methods (Cabrera et al, 2005; Kunkel et al, 2000; Maiorella et al, 1993; 
Schweikart et al, 1999), culture conditions (Kunkel et al, 2000; Maiorella et al, 
1993) and media composition (Cabrera et al, 2005; Serrato et al, 2007) to mention 
a few. There have been some previous studies monitoring glycosylation over the 
time-course of culture, to which similarities can be drawn from the results 
presented here. One was carried out by Goldman et al, 1998, who studied the 
glycosylation site-occupancy of interferon-gamma (IFN-y), which has three 
glycosylation sites, produced by NS0 cells. They did not observe any major
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variations in site-occupancy during perfusion culture, but noticed a slight decrease 
towards the later stages of stirred-tank culture. They also recorded changes in 
levels of sialylation over time; an increase in sialylation during the first 200 h of 
perfusion culture and then more constant levels, while sialylation during stirred- 
tank culture was fairly constant and then started to decrease after 200 h of culture. 
They reported that for both culture methods, maximal sialylation was associated 
with periods of rapid cell growth. Similarly, this is true for the highest levels of 
galactosylation recorded here as well, where decreased galactosylation was 
observed from early stationary phase and onwards. Goldman et al. (1998) suggest 
some similar explanations to those reported here when trying to explain the 
observed decreases; the action of extracellular sialidases released from lysed cells 
or compromised cellular sialylation (in our case galactosylation). They also 
suggest it could be due to the build-up of toxic metabolites, such as ammonia, 
which could possibly change the pH inside the cell to a sub-optimal one for 
sialyltransferase activity. Another report looking at glycosylation over time of 
culture was carried out by Robinson et al, 1994. This group characterised an IgGl 
produced through a prolonged fed-batch culture of NSO cells over 22 days. 
Glycosylation of proteins produced by NSO cells differ to that of those produced 
by CHO cells, but the main overall finding of an increase in truncated glycoforms 
is along the lines of our observations of an increase in glycoforms with lesser 
complexity later in culture. Robinson et al. (1994) also noted an increase in the 
amount of high-mannose oligosaccharides, which was not observed in our study. 
They ruled out glucose starvation and ammonia inhibition as possible reasons 
behind the behaviour and concluded that mAb production by non-viable cells and 
the release of incompletely processed mAb by lysed cells were negligible. 
Overall, the findings of this group support our hypothesis that the cells produce 
mAb with less complex glycans towards the later stages of culture, perhaps due to 
the high rates of product formation. No matter what the reasons behind the change 
in the glycosylation profile are, it is important to draw attention to the fact that 
they do take place. As mentioned, glycosylation is a post-translational 
modification of importance to for example stability and activity and therefore the 
efficacy when used as a pharmaceutical. Changes in the glycosylation profile have 
to be taken into careful consideration when designing the production process. It 
should be an important factor, along with cell growth and viability and mAh titres,
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in the decision making process as to when to harvest. The level of heterogeneity 
that is acceptable has to be agreed and the reproducibility is crucial for validation 
purposes. This study has not taken into consideration which is the most 
efficacious glycoform, but this has to be determined for each individual case and 
cause. The way forward then has to be discussed; is it feasible to harvest at the 
point when the desired glycoform is in abundance? It seems that glycoengineering 
would be a beneficial option, both in order to achieve highest possible efficacy of 
the product, but also to achieve batch-to-batch consistency and minimise any 
heterogeneity present.
The other aspect of the mAb structure that was closer looked at in this study is the 
overall composition of the H2L2 tetramer. From the spectra, it is obvious that a 
proportion of the mAb is present as HL dimers rather than tetramers, which is a 
trait of the IgG4 subclass and due to non-covalent bonds (Angal et al, 1993; 
Bloom et al, 1997; Deng et al, 2004; King et al, 1992; Zhang and Czupryn, 2002). 
The measurements are not quantifiable but give a good indication as to what is 
happening; the proportion of HL dimers is decreasing over time of culture. The 
reason for the decrease is not clear, but the important aspect from a process 
economics point of view is their existence. The HL dimers are not fully functional 
products and due to their different conformation they would be separated and 
removed during the last polishing steps in the purification process, for example by 
size exclusion or ion exchange chromatography. This means parts of the produced 
mAbs will be, despite being functional in theory, removed and discarded, 
resulting in a loss in yield. The sizes of these losses are not known and are outside 
the scope of this study; it is difficult to make an estimation due to the non- 
quantifiable detection methods, as well as possibly sub-optimal purification and 
storage procedures, compared to industrial processes. However, they could be 
substantial. One way of overcoming these problems is to use a different subclass 
than IgG4, or use genetic engineering to change the hinge region to that of for 
example IgGl or IgG2 (Angal et al, 1993; Bloom et al, 1997). However, if the 
IgG4 subclass is preferred, extensive research has to be carried out in order to 
minimize any losses due to these HL dimers. Attempts have been made to reduce 
their existence by for example media additions, such as copper sulphate, which 
creates an oxidative environment, facilitating the formation of disulphide bonds
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(Chaderjian et al, 2005) or by preventative screening for the most promising clone 
during cell line development (Deng et al, 2004).
The presence of the half-mAbs also brings further questions, such as; what 
physical conditions affect the proportion of dissociated tetramers? Are there more 
non-covalently bound mAbs in the final product? And if there are, will they stay 
bound or will they dissociate upon processing, formulation and storage? Some of 
these queries have been dealt with in the following studies in order to get a better 
understanding of the effect of processing on the conformation of the H2L2 
tetramer structure, as well as the glycosylation profile.
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5 Effect of harvest on the molecular structure and 
overall conformation of a mAb
5.1 Effect of shear on the glycosylation profile o f a mAb
This study examines the effect of means of cell removal after cultivation on the 
molecular structure of recombinant IgG. Ultra scale-down tools were applied to 
allow better prediction of the effects of early stage cell recovery by centrifugation 
on the structural authenticity of the protein. A shear-device mimicking the 
conditions at the inlet of a large-scale disc stack centrifuge was used to compare 
samples processed with or without shear.
5.1.1 Sampling overview
A 10 L fed-batch airlift fermenter was used (fermentation 1 from Chapter 4, for 
conditions see section 2.1) and samples were taken on three separate days for 
comparison (days 7, 14 and 17). Figure 5.1 shows the overview of the sampling 
protocol, for shearing and centrifugation conditions see sections 2.3 and 2.2 
respectively. Sample a) was not sheared and used as control, sample b) was 
sheared after centrifugation to study the effect of shear on the mAb itself, while 
sample c) was sheared prior to centrifugation in order to mimic the large scale 
process and study the effect of shear on the whole cell broth. Sample c) should 
also confirm whether the decreased complexity of the glycoforms observed in 
chapter 4 is due to the release of incompletely processed mAbs from lysed cells. 
All samples were purified using protein A chromatography (see section 2.6) and 
the intact mAb analyzed using the Agilent Bioanalyzer (see section 2.8.1) and 
time-of-flight mass spectrometry (see section 2.9.1).
5.1.2 Structural analysis
The Agilent Bioanalyzer was used to confirm the purity of the samples as well as 
investigate the effect of shear on the overall conformation of the mAb. Figure 5.2 
shows the electrophoresis data of the samples from days 7, 14 and 17. Proteins are 
present as intact mAbs at approximately 160 kDa and half-mAbs at 80 kDa, with 
no other contaminating proteins visible. Densitometric analysis of the gel reveals
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Figure 5.1 Sampling overview
Each day o f sampling, 60 mL broth was removed from the fermenter. 40 mL was 
centrifuged as described previously (see section 2 .2), the cells were discarded 
while the supernatant was split in two. The first part (a) was not treated with any 
shear, but only purified using protein A affinity chromatography (see section 2.6) 
and used as standard in the comparison. The second part (b) was sheared using 
standard conditions (see section 2.3) after removal o f cells but prior to protein A 
purification, to study the effect o f shear directly on the mAb. The remaining 20 mL 
(c) were sheared using standard conditions before centrifugation and purification 
so that the effect o f shear on the whole cell broth could be examined. The 
following denotations will be used; a) standard, b) sheared supernatant, c) 
sheared broth.
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Figure 5.2 Effect o f shear on mAb conformation
Bioanalyzer protein 200 assay after protein A chromatography. The samples are 
from days 7, 14 and 17, with the annotations from Figure 5.1: a ) no shear; b) 
sheared clarified mAb; c) sheared cell broth. The intact mAb can b e  seen with an 
approximate mass o f 160 kDa and a small proportion o f half-mAbs can also be 
seen at approximately 80 kDa. No other contaminating proteins are present. 
Water was used as control.
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Figure 5.3 Effect o f shear on the glycosylation profile of a mAb
The above figure shows the mass spectra from days 7, 14 and 17. Samples were 
treated as detailed in Figure 5.1, i.e. a) with no shear; b) sheared supernatant; c) 
sheared broth. Comparing the profiles for each day, i.e. looking down each o f the 
columns, the traces are very similar with only minor variations.
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there are no significant differences between samples treated with no shear, 
sheared clarified mAb or sheared cell broth, with regards to product composition 
and proportion of half-mAbs. There is one exception to this; the sheared clarified 
supernatant from day 7 shows half the proportion of HL dimers as compared to 
the non-sheared and the sheared cell broth. The reason behind this is unclear, but 
could just be due to a misrepresentative sample, since no trends are visible among 
the other samples. The analysis shows a decrease in the proportion of half-mAbs 
with time of culture, from -40% on day 7 to -9%  on day 17, supporting the 
results from section 4.4. The traces from the mass spectrometry analysis can be 
seen in Figure 5.3. For each of the days, the glycosylation profiles are very 
similar; no clear differences seem to have been caused by shear, either on the 
antibody itself (b) or the overall profile when intracellular material was released 
into the product stream (c). The minor differences that can be seen are most likely 
due to the deconvolution process. The results presented here indicate that shear 
during the first clarification step does not have an impact on the glycosylation 
pattern of mAbs, however, in order to confirm these findings, further experiments 
were designed and carried out as detailed in section 5.2.
5.2 Effect o f shear rate and time
From the previous investigation of the effect of shear on the glycosylation profile 
of the mAb (section 5.1) it looked as if shear during the first clarification step 
does not have an impact. In order to confirm this, a further shear study was carried 
out on a third fermentation. Here the rate and time of shearing was taken into 
consideration, since these would vary with the flow rate of a continuous large 
scale centrifuge and with the model used. Two different shear rates were used in 
addition to a control sample treated with no shear. Two different shear times were 
also used in addition to the control sample.
5.2.1 Sampling overview
Figure 5.4 shows the overview of the sampling protocol. In order to study the 
effect of both shear rate and time, two sets of samples were compared: a, b and d
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Figure 5.4 Sampling overview o f  shear investigation
A sample o f  100 mL was taken on day 13 o f culture and split into four. Each 20 
mL sample was purified the same way but with different shearing conditions. The 
first sample (a) was not sheared and used as control in the comparison. The 
remaining samples were sheared as follows; b) 15,000 rpm for 30 s, c) 15,000 
rpm fo r  90 s and d) 20,000 rpm for 30 s. All samples were centrifuged (see section 
2.2), the cell pellet discarded and the product-containing supernatant purified by 
protein A chromatography (see section 2.6).
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to look at the effect of shear rate with three different rates (no shear as control,
15.000 rpm and 20,000 rpm), all sheared for 30 s; a, b and c to look at the effect 
of shearing time with three different times (no shear as control, 30 s and 90 s), all 
sheared at 15,000 rpm. The intact mAb was analysed using LC/MSD-TOF (see 
section 2.9.1).
5.2.2 Structural analysis
The spectra in Figure 5.5 compare the glycosylation patterns of the mAbs treated 
with different shear rates. No significant differences can be seen in the traces, 
suggesting that shear rate does not have an impact on the glycosylation pattern of 
the mAb. The spectra in Figure 5.6 compare the glycosylation patterns of the 
mAbs exposed to shear for different lengths of time. Again no significant 
differences can be seen in the traces suggesting that the time the mAb is exposed 
to shear does not affect the glycosylation pattern either.
The spectra in Figure 5.7 look at the overall composition of the product stream 
with respect to half-mAbs and intact mAbs, after treatment with different shear 
rates. By visual inspection the proportion of HL dimers seem to increase upon 
treatment with shear, i.e. when comparing a) (treated without shear as a control) 
with b) and c) (sheared for 30 s at 15,000 rpm and 20,000 rpm respectively). 
However, when comparing the two different shear rates, i.e. 15,000 rpm and
20.000 rpm in b and c respectively, there seems to be no difference in the half- 
mAb proportion. This indicates that shear increases the proportion of dimers, but 
only to a certain extent; there seems to be an upper limit in how much the dimers 
can increase. In Table 5.1 the relative amounts of HL dimers and intact mAbs 
were calculated and the ratios were compared between the samples treated with 
different shear rates. The calculated ratios confirm the initial observations from 
Figure 5.7; there is an increase in half-mAb by approximately 9% upon shearing, 
but no increase from shearing at a higher rate. If then looking at the effect of 
shearing time on the overall conformation (Figure 5.8), similar results are 
observed. There is an increase in the proportion of half-mAbs upon shearing, i.e. 
comparing a) (no shear) with b) and c) (sheared at 15,000 rpm for 30 s and 90 s 
respectively), but no apparent increase when shearing for a longer time
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Figure 5.5 Effect o f shear rate on the glycosylation profile o f a mAb
The above figure shows the mass spectra o f the samples treated as detailed in 
Figure 5.4, i.e. a) with no shear; b) sheared at 15,000 rpm; d) sheared at 20,000 
rpm. No significant differences can be seen for the different shear rates.
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Figure 5.6 Effect o f shearing time on the glycosylation profile of a mAb
The above figure shows the mass spectra o f the samples treated as detailed in 
Figure 5.4, i.e. a) with no shear; b) sheared for 30 s; c) sheared fo r 90 s. No 
significant differences can be seen fo r  the different shearing times.
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Figure 5.7 Effect o f shear rate on the conformation of a mAb
The above figure corresponds to the spectra with the same denotation in Figure
5.5, with a) being treated with no shear as control, b) sheared at 15,000 rpm and
c) sheared at 20,000 rpm. There are three main peaks visible: non-glycosylated 
half-mAb; glycosylated half-mAb and intact mAb. By looking at the intensity o f 
the half-mAb peak, as compared to the intact mAb, b) and c) seem to be o f similar 
proportions, while a) has a slightly lower proportion o f half-mAb.
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Sample Half-mAb Half-mAb Intact mAb 
(non-glyc)
0 rpm 0 s 0.19 : 0.26 : 1
15k rpm 30 s 0.17 0.44 : 1
20k rpm 30 s 0.14 0.42 : 1
Table 5,1 Proportion o f HL dimers after shearing at different rates
From Figure 5.7 the relative amounts o f non-glycosylated half-mAbs, 
glycosylated half-mAbs and intact mAbs were measured and the ratios o f the three 
were calculated as can be seen in the table above. The first figure represents the 
non-glycosylated HL dimers, the second represents the glycosylated HL dimers 
and the third is the intact mAb, i.e. H2L2 tetramers. The spectral data is not 
quantifiable but any changes in proportions give an indication to differences 
between the samples. The data here supports the initial observations observed by 
eye in Figure 5.7; there is an increase in the proportion o f glycosylated half-mAb 
upon shearing (comparing a with b and c), but there seems to be no increase 
when shearing at a higher rate (comparing b and c).
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Figure 5.8 Effect o f shearing time on the conformation of a mAb
The above figure corresponds to the spectra with the same denotation in Figure
5.6, with a) being treated with no shear as control, b) sheared fo r  30 s and c) 
sheared fo r  90 s. There are three main peaks visible: non-glycosylated half-mAb; 
glycosylated half-mAb and intact mAb. By looking at the intensity o f the half-mAb 
peak, as compared to the intact mAb, b) and c) seem to be o f similar proportions, 
while a) has a slightly lower proportion o f half-mAb.
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Sample Half-mAb Half-mAb Intact mAb 
(non-glyc)
0 rpm 0 s 0.19 : 0.26 : 1
15k rpm 30 s 0.17 0.44 1
15k rpm 90 s 0.14 0.40 1
Table 5.2 Proportion o f HL dimers after shearing for different times
From Figure 5.8 the relative amounts o f non-glycosylated half-mAbs, 
glycosylated half-mAbs and intact mAbs were measured and the ratios o f the three 
were calculated as can be seen in the table above. The first figure represents the 
non-glycosylated HL dimers, the second represents the glycosylated HL dimers 
and the third is the intact mAb, i.e. H2L2 tetramers. The data here supports the 
initial observations observed by eye in Figure 5.8; there is an increase in the 
proportion o f  glycosylated half-mAb upon shearing (comparing a with b and c), 
but there seems to be no increase when shearing for a longer time (comparing b 
with c).
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(comparing b and c). Table 5.2 confirms these observations and shows that there 
is an increase in half-mAb by approximately 8% upon shearing, but no increase 
when shearing for a longer time.
5.3 Comparison o f intra- and extracellular mAb
In order to get a better understanding of the impact the release of intracellular 
material could have on the overall composition of the mAb, an investigation 
comparing the intra- and the extracellular mAb was carried out. The experiments 
detailed below were designed to determine any effects the release of intracellular 
material, due to cell lysis, could have on the overall composition of the product 
stream.
5.3.1 Sampling overview
Samples were taken on days 9 and 13 from the third GS-CHO fermentation as 
detailed in Figure 5.9. The sample was centrifuged to separate the cells from the 
product-containing supernatant. The cells were resuspended and homogenised to 
release any intracellular material, while the supernatant was immediately purified. 
Both samples were purified using protein A chromatography.
5.3.2 Structural analysis
After purification the intact mAb was analysed using time-of-flight mass 
spectrometry as before. The deconvoluted spectra from the analysis can be seen in 
Figure 5.10, showing the overall composition of the product. The extracellular 
material (9a and 13a) contains mainly HL dimers and intact mAbs. The proportion 
of HL dimers decreases from day 9 to day 13 in accordance with the findings 
from section 4.4. The intracellular material on the other hand (9b and 13b), 
contains barely any intact mAb, suggesting the mAbs are secreted immediately 
after assembly. The intracellular material is instead made up of single heavy 
chains, HL dimers and heavy chain dimers (HH). The proportion of each complex 
was calculated and listed in Table 5.3. This shows that the intracellular material 
from day 9 and day 13 are similar in composition, with the exception that the 
material from day 13 contains a larger proportion of non-glycosylated HL dimers 
and a smaller proportion of glycosylated single heavy chains.
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lOOmL
Centrifugation
Figure 5.9 Sampling overview
A sample o f  100 mL was taken on days 9 and 13 o f a 10 L fed-batch fermentation 
(see section 2.1). The sample was spun down using a bench-top centrifuge (for 
conditions see section 2.2) in order to separate the cells from the liquid broth. The 
mAbs were then purified from the supernatant (a) using protein A 
chromatography (for conditions see section 2.6). The cells (b) were resuspended 
and homogenised (see section 2.5) to release any intracellular material. The cell 
debris was then removed by centrifugation and the mAbs in the supernatant were 
purified by protein A. The mAbs were then purified using protein A 
chromatography as before.
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Figure 5.10 Comparison o f intra- and extracellular mAb
The figure above shows the spectra from days 9 and 13 where the samples were 
treated as detailed in Figure 5.9, with a) representing the extracellular product 
composition and b) the intracellular mAb composition. There are four main peaks 
visible in the spectra: a single heavy chain with a mass o f approximately 48 kDa; 
HL dimers at 73 kDa; complexes o f  two heavy chains at ~96 kDa; intact mAb at 
146 kDa. The extracellular material only shows the presence o f HL dimers and 
intact mAb, while the intracellular material show barely any intact mAb, some HL 
dimers, but also a large proportion o f  single heavy chains as well as complexes o f  
two heavy chains. Not visible in the spectra are the light chains since these are 
not captured by protein A.
140
Cecilia Reid Chapter 5
Sample H HL HH H2L2
9a 0.03 : 0.58 : 0.03 : 1
9b 1 : 0.43 : 0.63 : 0.02
13a 0.03 : 0.21 : 0.02 : 1
13b 1 : 0.47 : 0.88 : 0.02
Table 5.3 Compositions o f the intra- and extracellular material
From Figure 5.10, the relative amounts o f single heavy chains, HL dimers, heavy 
chain dimers (HH) and intact mAbs were measured and the ratios o f the four were 
calculated as can be seen in the table above. The first figure represents the single 
heavy chains, the second represents the HL dimers, the third the HH complexes 
and the fourth is the intact mAb, i.e. H2L2 tetramers.
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5.4 Discussion
As previously mentioned, several factors have been shown to affect the 
glycosylation pattern of mAbs, such as culture method (Cabrera et al, 2005; 
Kunkel et al, 2000; Maiorella et al, 1993; Schweikart et al, 1999), culture 
conditions (Kunkel et al, 2000; Maiorella et al, 1993) and media composition 
(Cabrera et al, 2005; Serrato et al, 2007). However, these studies are all looking at 
the cultivation step and so far little attempt has been made to investigate the 
effects of further processing on the detailed molecular structure. The first 
processing step after culture is most commonly centrifugation. This unit operation 
is known to exert certain levels of shear on the material, which could have 
detrimental effects, especially with regards to solids carryover (Hutchinson et al, 
2006). In the study by Hutchinson et al. (2006), SDS-PAGE was used to compare 
the mAbs after treatment with shear. This technique showed a stable product, 
which has been confirmed here by the Bioanalyzer data. Shearing of either cell 
broth or supernatant does not seem to have an effect on the glycosylation pattern, 
as revealed by the mass spectra. Shear rate and time does not impact the 
molecular structure of the mAb either. This means that with regards to mAb 
stability and structure, different types of centrifuges, causing different amounts of 
shear, can be used in mAb production, without concern of impacting the 
molecular structure of the product. However, from the studies carried out here, it 
has become obvious that shear does have an effect on the overall conformation of 
the mAb with respect to the proportion of HL dimers. Shear increases the 
proportion of dimers to a certain level, above which there seems to be no further 
increase. The increase seems to be apparent immediately upon shearing and the 
rate or time that the product stream is exposed to shear does not have an effect 
once this upper limit has been reached. This phenomenon is connected to IgG4, 
rather than being a general concern for all mAbs or therapeutic proteins, due to 
the existence of non-covalently bound H2L2 tetramers caused by the hinge-region 
of the IgG4 molecule (King et al, 1992). These findings suggest that IgG4 in 
particular is sensitive to shear with regards to product integrity and that this 
should be carefully considered when designing the purification process. However, 
shear in the purification process should be avoided for all mAb subclasses due to
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solids carryover, as previously mentioned. Shear during centrifugation does 
increase solids carryover, so with regards to process economics, where larger 
filter areas would have to be used after clarification using high-shear centrifuges, 
a lower shear centrifuge would still be favourable. This study did not include 
specific activity measurements, but the data still gives a good indication that shear 
does not affect activity of the mAb, since the glycosylation pattern remained the 
same upon shearing and glycosylation in turn has been linked to mAb activity 
(Lund et al, 1996; Mimura et al, 2000). The intracellular material from day 13 
contains a larger proportion of non-glycosylated half-mAbs compared to day 9. 
This could be related to the decrease in glycoform complexity with time of 
culture, as discussed in chapter 4 and could be due to the glycosylation machinery 
not being able to cope with the large amount of mAbs being produced. The 
spectra of the overall composition of the intracellular material shows the presence 
of single heavy chain as well as HH dimers in addition to the HL dimers that are 
detected in the extracellular material. Since these two complexes are not present 
in the extracellular product stream this indicates that the increase in HL dimers is 
caused by dissociation of H2L2 tetramers upon shearing rather than the release of 
any intracellular material due to cell lysis, or all three complexes would be present 
in the extracellular material. The intracellular material also shows very low levels 
of intact mAb. This suggests that the H2L2 tetramers are secreted immediately 
upon assembly. This in turn means that, even if there is a significant amount of 
intracellular material (in this case -10%), there is no functional product that is 
being lost, but instead cell lysis, due to ageing cells or shear, would only increase 
the levels of unwanted product variants such as single heavy chains, half-mAbs 
and HH chain complexes. This also speaks in favour of using low-shear 
centrifuges in order to minimise the load on expensive subsequent 
chromatography steps.
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6 Effect of holding time and conditions in between 
stages
During downstream processing of biopharmaceuticals it is sometimes necessary to 
add holding stages when unit operations are operated at different flow rates or in a 
batch mode. This study examines what effects holding time and conditions could 
have on the molecular structure of mAbs. Samples were taken on day 13 of a 
fermentation as detailed in Figure 6.1 and held at two different temperatures 
(+4°C and +37°C) for different lengths of time (2 h, 4 h and 24 h). One sample 
was processed immediately, before holding, as a control for both temperatures. 
The samples were then treated as detailed in Figure 6.2, with or without shear. 
Shear can be experienced for example due to mixing in the holding tank, in 
pumps, or in the subsequent clarification step and might have a detrimental effect 
on the process, with increased filtration membrane areas due to increased debris 
carryover (Hutchinson et al, 2006). The following chapter gives an indication to 
the effects a holding stage could have on the molecular structure and the overall 
composition of the IgG studied and how shear experienced in the subsequent 
centrifugation step could affect the integrity and composition of the mAb. They 
should also give some insight as to whether the decrease in complexity of the 
glycoforms with increased cultivation time as reported in chapter 4 could be 
caused by chemical degradation. This was done by choosing a holding 
temperature of +37°C mimicking the conditions during the fermentation, while the 
other temperature, +4°C, was chosen to mimic the effects of keeping the broth in a 
chilled container.
6.1 Effect o f holding on molecular structure and glycosylation
The effect of holding cell culture broth at +4°C and +37°C after harvest on the 
molecular structure of a recombinant mAb can be seen in Figure 6.3 and Figure 
6.5 respectively. The traces show the structure of the intact mAb as analyzed by 
time-of-flight mass spectrometry (see section 2.9.1). From both sets of data no 
trends can be seen by visual inspection, only minor variations occur and are most 
likely due to the deconvolution process. For all samples studied the G0F/G1F 
glycoform is the most abundant. In order to get a closer look and determine in
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Figure 6.1 Sampling overview
Seven samples o f 40 mL were taken on day 13 o f a 10 L fermentation (see section 
2.1). One o f  these samples was treated immediately as detailed in Figure 6.2 as a 
control. Three o f the samples (upper half o f Figure 6.1) were kept on hold at 
+4°C fo r  2 h, 4 h, or 24 h respectively before treated as detailed in Figure 6.2. 
The remaining three samples (lower half o f Figure 6.1) were kept on hold at 
+37°C also fo r  2 h, 4 h and 24 h respectively and then treated as Figure 6.2.
Purification a
20 mL
DiscardNo shear
Purification b20 mL
Shear Discard
Centrifugation
Figure 6.2 Sample treatment
From Figure 6.1, each 40mL sample was treated as the above figure shows; 20 
mL were centrifuged using a regular benchtop centrifuge (see section 2.2) and the 
supernatant then purified using protein A chromatography (see section 2.6) 
before analysis. This sample was used as the base case for looking at the effect o f 
holding. The other 20 mL were first sheared and then clarified, the supernatant 
then purified and analysed. This sample shows the effect o f shear after holding.
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Figure 6.3 Effect o f holding at +4°C on the molecular structure of a mAb
The mass spectra obtained from the samples o f the upper half o f  Figure 6.1, i.e. a 
sample was taken from the broth and treated as detailed in Figure 6.2 without 
shear (a) or with shearing (b), after being kept on hold at +4°C for 0 h, 2 h, 4 h 
and 24 h respectively. The mass spectra have been zoomed in around the intact 
mAb, from 146,000 Da to 148,000 Da. All data sets are shown to help determine 
i f  there are any trends visible. As determined by eye, the spectra all seem
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identical, only with minor variability. These are most likely to be due to the 
deconvolution software rather than molecular differences.
Figure 6.4 Comparison o f the two most extreme samples from Figure 6.3
The two most extreme samples, 0 h treated with no shear (a-0) and 24h o f holding 
at +4°C treated with shear (b-24), have been overlaid. No significant differences 
in the traces can be observed.
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Figure 6,5 Effect o f holding at +37°C on the molecular structure of a mAb
The mass spectra obtained from the samples o f  the lower half o f  Figure 6.1, i.e. a 
sample was taken from the broth and treated as detailed in Figure 6.2 without 
shear (a) or with shearing (b), after being kept on hold at +37°C for 0 h, 2 h, 4 h 
and 24 h respectively. The mass spectra have been zoomed in around the intact 
mAb, from 146,000 Da to 148,000 Da. As for Figure 6.3, the spectra all seem 
identical, only with minor variability, due to the deconvolution process.
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Figure 6.6 Comparison of the two most extreme samples from Figure 6.5
The two most extreme samples, 0 h treated with no shear (a-0) and 24h o f holding 
at +3 7°C treated with shear (b-24), have been overlaid. No significant differences 
in the traces can be observed.
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more detail how similar the spectra are, the traces of the two most extreme 
samples; non-sheared at 0 h and sheared at 24 h, have been overlaid in Figure 6.4 
and Figure 6.6 for +4°C and +37°C respectively. Here it becomes more obvious 
that the traces are close to identical, which confirms the observations made that 
neither holding nor shear has an effect on the molecular structure and the 
glycosylation profile of the mAb.
6.2 Effect o f holding on mAb conformation
The integrity of the intact mAb is the main concern during production and 
purification, since it makes up the final product. However, the composition of the 
product stream is also of great importance during downstream processing, since 
any product variants will load up the chromatography columns. If the variants are 
separated out as non-fully functional, this will also lower the important overall 
yield. As explained in section 1.6.4, the IgG4 mAb is co-produced with a non- 
covalently linked version of the mAb, which is prone to disassociation into two 
HL dimers, “half-mAbs”. Rather than looking at only the effect of holding on the 
detailed molecular structure of the intact mAb, the impact on the molecular 
integrity of the molecule can be assessed. Figure 6.7 and Figure 6.8 show the 
mass spectrometry profiles as an overview of all protein A-positive material in the 
product stream, for holding at +4°C and +37°C respectively. Three main peaks 
can be identified; non-glycosylated half-mAb, glycosylated half-mAb and intact 
mAb (glycosylated). In order to determine whether holding time and conditions, 
together with harvest method, have any effect on the proportion of half-mAb, the 
relative amounts of the three structures were measured and the ratios between 
them were calculated as half-mAb (non-glycosylated) : half-mAb (glycosylated) : 
intact mAb, as listed in Table 6.1 and Table 6.2 for +4°C and +37°C respectively. 
These tables show that the proportion of non-glycosylated half-mAb does not 
appear to be affected by either holding conditions (+4°C or +37°C), holding time 
(0 h -  24 h) or harvest conditions (no shear or shear), but stays level throughout 
all treatment conditions. The proportion of glycosylated half-mAb on the other 
hand, seems to be affected to a certain level. At both +4°C and +37°C the 
proportion of these HL dimers seems to increase when exposed to shear. Of the 
total protein A positive material, there is an increase in the proportion of
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Figure 6.7 Effect o f holding at +4°C on the proportion of HL dimers
The traces correspond to the samples with the same annotation in Figure 6.3, but 
here the whole range o f  masses are shown as an overview, from 10,000 Da to 
180,000 Da. Three main distinct peaks can be seen that are actually clusters o f 
peaks when looking more closely, corresponding to the different modifications 
and glycosylation patterns present. There is one group just under 72,000 Da,
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which corresponds to non-glycosylated HL dimers, i.e. “half-Abs”. The second 
one is the glycosylatedform o f  the HL dimer, with masses on 73,000 Da. The third 
peak cluster is the intact mAb, with the main peak at 146,634 Da, corresponding 
to the mAb with both C-terminal lysine residues cleaved o ff (OK), both N-terminal 
glutamine residues converted to pyroglutamic acid (pE) and with the G0F/G1F 
glycoform. From determination by eye, looking down each column, i.e. looking at 
the effect o f  holding time on the product composition, the proportion o f half-mAb 
(both non-glycosylated and glycosylated) does not seem to change with time (Oh, 
2h, 4h and 24h), fo r  either non-sheared samples (a) or those treated with shear 
(b). I f  instead comparing the two columns at each time point, e.g. a-2 and b-2, 
there seems to be an increase in the proportion o f half mAbs when the sample has 
been exposed to shear. The increase is not o f a major magnitude, but seems 
consistent and could be o f  importance. The non-glycosylated proportion does not 
seem affected by shear.
No shear
Half-mAb
(non-glyc)
Half-mAb Intact
mAb
Shear
Half-mAb
(non-glyc)
Half-mAb Intact
mAb
Oh 0.14 0.22 : 1 0.11 0.31 1
2 h 0.14 0.22 : 1 0.12 0.30 1
4 h 0.13 0.22 : 1 0.13 0.37 1
24 h 0.13 0.21 : 1 0.13 0.34 1
Table 6.1 Proportion o f HL dimers after holding at +4°C
From Figure 6.7, the relative amounts o f non-glycosylated half-mAbs, 
glycosylated half-mAbs and intact mAbs were measured and the ratios o f the three 
were calculated as can be seen in the table above. The first figure represents the 
non-glycosylated HL dimers, the second represents the glycosylated HL dimers 
and the last is the intact mAb. These calculations confirm the initial observations 
as detailed under Figure 6.7; the proportion o f non-glycosylated mAb stays the 
same both with holding time and with shear treatment. The proportion o f 
glycosylated half-mAb also stays level with increasing holding time, but from 
treatment with shear the proportion increases by 5-7 % from 16 Vo to 21-25 % o f  
total protein A positive material.
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Figure 6.8 Effect of holding at +37°C on the proportion of HL dimers
The traces correspond to the samples with the same annotation in Figure 6.5, but 
here the whole range o f  masses are shown as an overview, from 10,000 Da to
180.000 Da. The three main peaks are peak clusters o f mAbs with different 
modifications and glycosylation patterns as in Figure 6.5. The group just under
72.000 Da corresponds to non-glycosylated HL dimers, the second group is the
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glycosylated half-mAbs and the third peak is the intact mAb. Looking down the 
two columns, i.e. looking at the effect o f  holding time on the product composition, 
the proportion o f non-glycosylated HL dimers does not seem to change with time 
(Oh, 2h, 4h and 24h), fo r  either non-sheared samples (a) or those treated with 
shear (b). The same is the case fo r  glycosylated HL dimers treated with shear (b). 
The samples not exposed to shear, on the other hand, (a-0, a-2, a-4 and a-24) the 
proportion o f  glycosylated half-mAbs seems to increase slightly. I f  instead 
comparing the two columns at each time point, e.g. a-2 and b-2, there seems to be 
an increase in the proportion o f  half mAbs when the sample has been exposed to 
shear. The non-glycosylated proportion does not seem affected by shear.
No shear
Half-mAb
(non-glyc)
Half-mAb Intact
mAb
Shear
Half-mAb
(non-glyc)
Half-mAb Intact
mAb
Oh 0.14 : 0.22 1 0.11 0.31 1
2 h 0.13 : 0.23 1 0.13 0.33 1
4 h 0.14 : 0.25 1 0.14 0.36 1
24 h 0.15 : 0.30 1 0.16 0.30 1
Table 6.2 Proportion o f HL dimers after holding at +37°C
The relative amounts o f  non-glycosylated half-mAbs, glycosylated half-mAbs and 
intact mAbs were measured from  Figure 6.8 o f non-glycosylated half-mAbs, 
glycosylated half-mAbs and intact mAbs were measured and the ratios o f  the three 
were calculated as can be seen in the table above. The first figure represents the 
non-glycosylated HL dimers, the second represents the glycosylated HL dimers 
and the last is the intact mAb. These calculations are in accordance with the 
initial observations as detailed under Figure 6.8. The proportion o f non- 
glycosylated mAb stays the same both with holding time and with shear treatment. 
The proportion o f  glycosylated half-mAbs also stays the same for the samples 
treated with shear. As fo r  holding at +4°C (Table 6.1), the proportion o f 
glycosylated half-mAb increases on exposure to shear, this time by 6% for three o f 
the time points and by 1% fo r  24 h; from 16-21% to 22-24% o f total protein A 
positive material. For the non-sheared samples, there is an increase o f 5% o f  
glycosylated half-mAbs with holding time from 0 to 24 h. The levels o f half-mAbs 
here reach the same levels as when the mAbs are exposed to shear.
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glycosylated half-mAbs from approximately 16% to 22% upon shearing, an 
increase of 6%. If instead looking at the effect of holding time; at +4°C the 
proportion of glycosylated half-mAbs does not seem affected by holding for 0 h -  
24 h. At +37°C on the other hand, there is an increase in these half-mAbs, 
reaching the same levels after 24 h as is experienced when the mAbs are exposed 
to shear; the higher temperature causing an increase in HL dimers.
6.3 Discussion
During large-scale production of therapeutic proteins it is often necessary to have 
holding stages in between unit operations. This can be due to several reasons; the 
different units have to be run at different flow rates during continuous operation, 
or a stage has to be run in batch mode and parts of the broth will then have to be 
kept on hold prior to the subsequent processing step. An example of units being 
operated at different flow rates is centrifugation, where relatively high flow rates 
can be expected (170-600 L h '1), and chromatography, where the flow rates are 
much lower (30-200 cm h '1). The experiments outlined here were designed to look 
at the interaction between the fermentation, in this case a fed-batch operation, and 
the subsequent harvest step. The data presented in this chapter also shows the 
most abundant glycoform to be the G0F/G1F structure, which fits in well with the 
profiles reported over time in chapter 4. Exposing the mAb to shear that would be 
experienced in a large-scale centrifuge after the holding stage does not have an 
effect on the glycosylation pattern either, causing no concerns about 
centrifugation conditions in this aspect.
In chapters 4 and 5 the presence of HL dimers, or half-mAbs, was also reported. 
This chapter gives some insight to how a holding stage could affect the amount of 
these product variants. It also helps answering some of the questions that were 
raised in the previous chapters relating to the reasons behind changes in half-mAb 
proportions. The holding stage used could mimic an actual holding stage in 
between processes, but could also give some insight as to what would happen 
upon storage of the mAbs. Formulation would of course put the mAbs in a more 
suitably protected environment, but this study should still give an indication of the
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stability of the H2L2 tetramers. Looking at the overall conformation of the mAb 
and the proportion of HL dimers in the product stream, the holding stage and 
further processing seem to have an impact on the product integrity, depending on 
the holding conditions. Holding at +4°C seems to have a lesser impact than 
holding at +37°C, with no effect on half-mAb levels with increased holding time. 
At +37°C there seems to be an increase in glycosylated half-mAb with longer 
holding times, suggesting that the higher temperature puts the cells in a non- 
favourable condition. Looking at the effect of shear treatment, the results for the 
two different temperatures are more similar. The noted levels of glycosylated half- 
mAbs are fairly constant over the sheared samples at both +4°C and +37°C, with 
an increase in half-mAbs after shearing for most samples by 5-7%. This is 
considered a significant increase since four repeat injections gave variations of 
±2%. The increase could be either due to cell lysis caused by shear and the 
subsequent release of incompletely assembled HL dimers or it could be due to the 
shear forces causing dissociation of the non-covalently bound H2L2 tetramers. The 
main difference between the two temperatures is that at +37°C, after holding for 
24 hrs, there is no increase when comparing the non-sheared and the sheared 
sample. However, for this sample an increase in glycosylated half-mAbs had 
already been observed due to holding time and the proportion of these HL dimers 
was already at the same level observed in all of the sheared samples. The data 
suggests that both temperature and shear cause an increase in HL dimers, which 
could be either due to cell lysis and the subsequent release of HL dimers or shear 
causing the H2L2 tetramers to dissociate. The data also suggests that due to the 
stronger nature of the bond, the covalently bound tetramers are not affected. The 
results reported here have to be carefully taken into consideration when designing 
production and purification processes for IgG4. Even though the glycosylation 
pattern of the mAb does not seem affected by holding or processing, holding at an 
elevated temperature as well as treatment with shear has an affect on the overall 
product composition. When manufacturing IgG4, precautions have to be taken in 
order not to lose a proportion of the valuable product. As suggested before, this 
could be done by preventative screening for the most promising clone during cell 
line development (Deng et al, 2004), or by facilitating the formation of disulphide 
bonds through media additions, such as copper sulphate (Chaderjian et al, 2005), 
or alternatively by genetic engineering (Angal et al, 1993; Bloom et al, 1997).
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7 Overall discussion
A number of important observations have been made and discussed in the 
chapters detailing the studies that were carried out. In addition to this, the data 
from the separate experiments can be linked together putting together a bigger 
picture and more conclusions can be drawn from this. In chapter 6 it was 
concluded that neither holding time nor temperature has an effect on the 
glycosylation pattern of the mAb. This can be linked to the studies carried out in 
chapter 4 and the observation that the glycosylation profile changes with 
cultivation time. It suggests that the changes in glycosylation profile are not due to 
the prolonged time the product is being kept in the broth and possible proteolytic 
degradation. Instead the changes have to be due to one or both of the other two 
suggested causes: the cells producing incompletely processed material due to 
stress; release of incompletely processed material due to cell lysis. The data 
presented in chapter 6 also shows that the most abundant glycoform is the 
G0F/G1F structure, which fits in well with the profiles reported over time in 
chapter 4.
In chapters 4 and 5 the presence of HL dimers, or half-mAbs, was also reported. 
This raised a number of questions regarding processing and its effects on the 
levels of half-mAbs: What physical conditions affect the proportion of dissociated 
tetramers? Are there more non-covalently bound mAbs in the final product than 
the ones that have dissociated into HL dimers? And if there are, will they stay 
bound or dissociate upon processing, formulation and storage? The studies in 
chapter 6 were designed to answer some of these questions. The data suggests that 
both temperature and shear during a potential holding stage cause an increase in 
HL dimers, which could be either due to cell lysis and the subsequent release of 
HL dimers or shear causing the H2L2 tetramers to dissociate. Looking back at the 
findings from chapter 5, it was established that the increase in HL dimers was 
most likely due to dissociation due to shear rather than cell lysis since no single 
heavy chains or HH dimers are present in the product stream. This suggests that 
holding time and temperature should be carefully considered and damaging shear 
rates should be avoided when designing manufacturing processes for IgG4 and 
similar therapeutic proteins.
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8 Conclusions
ESI-TOF analysis of intact mAb has proved to be a very useful technique for 
monitoring glycosylation as well as the proportion of HL dimers and other 
contaminating complexes. The technique provides a straightforward way to cut 
down on time and cost of sample preparation.
The IgG used in this study showed heterogeneity due to glycosylation, C-terminal 
lysine reidues and N-terminal glutamine residues, with two thirds of the mAb 
having both lysine residues cleaved off and most mAb both glutamine residues 
converted to pyroglutamic acid. The data presented here also showed that two 
different glycans can be attached to the heavy chains of the same mAb causing 
even more heterogeneity.
A decrease in glycan complexity was observed with time of culture, with reduced 
levels of galactosylation towards the later stages of fermentation, the (G0F)2 
glycoform being the most abundant at time of harvest. Shearing, regardless of rate 
and time, had no effect on glycosylation and neither does holding time or 
temperature.
HL dimers were observed in the purified product stream due to the presence of 
non-covalently bound H2L2 tetramers. Holding time did not affect the proportion 
of half-mAbs at +4°C, but an increase could be seen after 24 hrs holding at +37°C. 
Shearing caused a 10% increase in the proportion of HL dimers, regardless of 
shear rate and time, as compared to a non-sheared control. The increase in half- 
mAb appeared to be due to shear causing the non-covalently bound tetramers to 
dissociate rather than due to the release of incompletely processed material from 
cell lysis.
The ultimate outcome of the work presented is a tool-kit (Figure 8.1) for in- 
process analysis of complex biopharmaceuticals. This entails sampling from 
culture broth, product capture and at-line mass spectrometry analysis of the intact 
protein, without the need for extensive sample preparation.
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Figure 8.1 Schematic o f  the tool-kit
The ultimate outcome o f  this work is a tool-kit for in-process determination o f the 
structural and conformational authenticity o f complex biopharmaceuticals. This is 
briefly summarised in the above flow diagramme and entails sampling from  
fermentation broth and the use o f  ultra scale-down methodologies, including the 
shear device, followed by purification, online desalting and at-line analysis o f the 
intact protein, cutting out extensive sample preparations like enzymatic digests.
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9 Future work
Glycosylation has previously been linked to activity of mAbs, which is why this 
post-translational modification was the main concern in the work presented here. 
A decrease in galactosylation with time of culture of a recombinant IgG4 was 
shown, suggesting time of harvest could have an impact on the activity of the 
product. However, activity studies were not included in this study and would have 
to be carried out in order to confirm the actual effects on product efficacy. This 
would then lead to further investigations regarding the most optimal time to 
harvest with respect to product activity.
The presence of HL dimers in the product stream after protein A chromatography 
was also presented and how the proportion of these product variants increases 
upon exposure to shear. The final polishing steps, such as size exclusion 
chromatography, would eliminate the half-mAbs, but would then lead to a 
proportion of the final product being removed and therefore losses in final yield. 
The size of these losses was outside the scope of this study, but should be 
investigated further in order to get an estimation of the effect on the overall 
process economics. Some studies elsewhere have attempted to minimize the 
presence of the HL dimers, but additional, more efficient ways, would be 
beneficial to find for the cases where IgG4 is the desirable subclass.
All studies presented here were carried out at small-scale and supported by 
previous work should give a good representation of the large-scale process. 
However, it would be beneficial to carry out the same experiments at pilot- or 
large-scale to confirm this is the case.
The ESI-TOF analysis of intact mAb provided a time-saving technique for protein 
analysis and glycosylation monitoring. This inspires even further time- and 
labour-saving thinking around bottlenecks in process evaluation and automation 
in monitoring protein production. Would online purification and analysis of mAbs 
and other therapeutic proteins be possible? Could a sample be taken from the 
culture broth and without extensive sample preparations be analyzed using mass
160
spectrometry and how long would this take? Would it be possible to cut down 
analysis time from days to a few hours?
Therapeutic proteins and mAbs in particular have infiltrated the pharmaceutical 
market very fast over the past decades, offering treatments for diseases that have 
so far been difficult to treat. During these years a lot of research has gone into 
studying mAb production and purification and processes have been greatly 
improved since the beginning. However, there is still a lot of work to be done in 
order to fully understand what effects production and processing conditions have 
on structure and efficacy and to improve the processes currently in place.
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